|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Roxithromycin results in decreased expression of BCL2 protein |
CTD |
PMID:12921874 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases activity |
ISO |
Roxithromycin results in decreased activity of CYP2B6 protein |
CTD |
PMID:17164692 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions decreases expression decreases activity |
ISO |
Roxithromycin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone] Roxithromycin results in decreased expression of CYP3A4 mRNA Roxithromycin results in decreased activity of CYP3A4 protein |
CTD |
PMID:16416302 PMID:16837568 PMID:17164692 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
Roxithromycin results in increased expression of FASLG protein |
CTD |
PMID:12921874 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Roxithromycin results in increased expression of FOS mRNA; Roxithromycin results in increased expression of FOS protein |
CTD |
PMID:32454074 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Roxithromycin inhibits the reaction [Mustard Gas results in increased expression of IL1B mRNA]; Roxithromycin inhibits the reaction [Mustard Gas results in increased expression of IL1B protein] Roxithromycin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] |
CTD |
PMID:17524151 PMID:18197913 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Roxithromycin inhibits the reaction [Mustard Gas results in increased expression of IL6 mRNA]; Roxithromycin inhibits the reaction [Mustard Gas results in increased expression of IL6 protein] |
CTD |
PMID:17524151 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgb4 |
integrin subunit beta 4 |
decreases expression |
ISO |
Roxithromycin results in decreased expression of ITGB4 protein |
CTD |
PMID:14687228 |
|
NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
decreases expression |
ISO |
Roxithromycin results in decreased expression of LAMC2 protein |
CTD |
PMID:14687228 |
|
NCBI chr13:65,284,664...65,344,200
Ensembl chr13:65,284,664...65,344,200
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
EXP |
Roxithromycin inhibits the reaction [Lipopolysaccharides results in increased expression of MUC5AC mRNA]; Roxithromycin inhibits the reaction [Lipopolysaccharides results in increased expression of MUC5AC protein] |
CTD |
PMID:18197913 |
|
NCBI chr 1:196,864,375...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
Roxithromycin inhibits the reaction [Diethylnitrosamine results in increased activity of [NFKB1 protein binds to RELA protein]] |
CTD |
PMID:16061884 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Roxithromycin inhibits the reaction [Mustard Gas results in increased expression of NOS2 protein] Roxithromycin inhibits the reaction [Diethylnitrosamine results in increased activity of NOS2 protein] |
CTD |
PMID:16061884 PMID:17524151 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Roxithromycin inhibits the reaction [Diethylnitrosamine results in increased activity of [NFKB1 protein binds to RELA protein]] |
CTD |
PMID:16061884 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
Roxithromycin inhibits the reaction [Mustard Gas results in increased expression of TNF mRNA]; Roxithromycin inhibits the reaction [Mustard Gas results in increased expression of TNF protein] Roxithromycin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:17524151 PMID:18197913 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions increases expression decreases response to substance decreases expression decreases activity |
ISO EXP |
abamectin inhibits the reaction [ABCB1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride] abamectin results in increased expression of ABCB1A mRNA [Ascorbic Acid co-treated with Sesame Oil] inhibits the reaction [abamectin results in increased expression of ABCB1A mRNA]; Ascorbic Acid inhibits the reaction [abamectin results in increased expression of ABCB1A mRNA]; Sesame Oil inhibits the reaction [abamectin results in increased expression of ABCB1A mRNA] ABCB1A protein results in decreased susceptibility to abamectin abamectin results in decreased expression of ABCB1A protein abamectin results in decreased activity of ABCB1A protein abamectin inhibits the reaction [ABCB1A protein results in increased transport of bisbenzimide ethoxide trihydrochloride] abamectin results in decreased activity of ABCB1 protein |
CTD |
PMID:9144452 PMID:17134887 PMID:19879343 PMID:25865432 PMID:31739238 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions decreases activity |
ISO |
abamectin inhibits the reaction [ABCC1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride] abamectin results in decreased activity of ABCC1 protein |
CTD |
PMID:25865432 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Actb |
actin, beta |
decreases expression |
ISO |
abamectin results in decreased expression of ACTB protein |
CTD |
PMID:19879343 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression |
ISO |
abamectin results in decreased expression of AKT1 protein |
CTD |
PMID:30958899 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Ano1 |
anoctamin 1 |
decreases activity |
ISO |
abamectin results in decreased activity of ANO1 protein |
CTD |
PMID:32201246 |
|
NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions increases expression |
EXP |
Hesperidin inhibits the reaction [abamectin results in increased expression of ATF6 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP |
Hesperidin inhibits the reaction [abamectin results in increased expression of BAX mRNA]; Hesperidin inhibits the reaction [abamectin results in increased expression of BAX protein] abamectin results in increased expression of BAX mRNA; abamectin results in increased expression of BAX protein |
CTD |
PMID:34748272 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP |
Hesperidin inhibits the reaction [abamectin results in decreased expression of BCL2 mRNA]; Hesperidin inhibits the reaction [abamectin results in decreased expression of BCL2 protein] abamectin results in decreased expression of BCL2 mRNA; abamectin results in decreased expression of BCL2 protein |
CTD |
PMID:34748272 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Becn1 |
beclin 1 |
increases expression multiple interactions |
EXP |
abamectin results in increased expression of BECN1 protein Hesperidin inhibits the reaction [abamectin results in increased expression of BECN1 protein] |
CTD |
PMID:34748272 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Casp3 |
caspase 3 |
increases activity increases expression multiple interactions |
ISO EXP |
abamectin results in increased activity of CASP3 protein abamectin results in increased expression of CASP3 mRNA; abamectin results in increased expression of CASP3 protein [Ascorbic Acid co-treated with Sesame Oil] inhibits the reaction [abamectin results in increased expression of CASP3 protein]; Ascorbic Acid inhibits the reaction [abamectin results in increased expression of CASP3 protein]; Hesperidin inhibits the reaction [abamectin results in increased expression of CASP3 mRNA]; Hesperidin inhibits the reaction [abamectin results in increased expression of CASP3 protein]; Sesame Oil inhibits the reaction [abamectin results in increased expression of CASP3 protein] |
CTD |
PMID:30958899 PMID:31739238 PMID:34748272 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions decreases activity increases activity |
EXP |
[Ascorbic Acid co-treated with Sesame Oil] inhibits the reaction [abamectin results in increased activity of CAT protein]; Ascorbic Acid inhibits the reaction [abamectin results in increased activity of CAT protein]; Hesperidin inhibits the reaction [abamectin results in decreased activity of CAT protein]; Sesame Oil inhibits the reaction [abamectin results in increased activity of CAT protein] |
CTD |
PMID:31739238 PMID:34748272 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions increases expression |
EXP |
[Ascorbic Acid co-treated with Sesame Oil] inhibits the reaction [abamectin results in increased expression of CYP2E1 protein]; Ascorbic Acid inhibits the reaction [abamectin results in increased expression of CYP2E1 protein]; Sesame Oil inhibits the reaction [abamectin results in increased expression of CYP2E1 protein] |
CTD |
PMID:31739238 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases expression multiple interactions |
EXP |
abamectin results in increased expression of EIF2AK3 mRNA Hesperidin inhibits the reaction [abamectin results in increased expression of EIF2AK3 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
increases expression multiple interactions |
EXP |
abamectin results in increased expression of ERN1 mRNA Hesperidin inhibits the reaction [abamectin results in increased expression of ERN1 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases expression |
EXP |
Hesperidin inhibits the reaction [abamectin results in decreased expression of HMOX1 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression multiple interactions |
EXP |
abamectin results in increased expression of HSPA5 mRNA Hesperidin inhibits the reaction [abamectin results in increased expression of HSPA5 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP |
abamectin results in increased expression of IL1B mRNA Hesperidin inhibits the reaction [abamectin results in increased expression of IL1B mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
EXP |
Hesperidin inhibits the reaction [abamectin results in increased expression of IL6 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jak2 |
Janus kinase 2 |
increases expression multiple interactions |
EXP |
abamectin results in increased expression of JAK2 mRNA Hesperidin inhibits the reaction [abamectin results in increased expression of JAK2 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Map1lc3a |
microtubule-associated protein 1 light chain 3 alpha |
multiple interactions increases expression |
EXP |
Hesperidin inhibits the reaction [abamectin results in increased expression of MAP1LC3A mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases expression |
EXP |
Hesperidin inhibits the reaction [abamectin results in increased expression of MAP1LC3B mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
increases expression multiple interactions |
EXP |
abamectin results in increased expression of MAPK14 mRNA Hesperidin inhibits the reaction [abamectin results in increased expression of MAPK14 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions decreases expression |
EXP |
Hesperidin inhibits the reaction [abamectin results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression multiple interactions |
EXP |
abamectin results in increased expression of NFKB1 mRNA Hesperidin inhibits the reaction [abamectin results in increased expression of NFKB1 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
abamectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; abamectin inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression |
ISO |
abamectin results in decreased expression of SQSTM1 protein |
CTD |
PMID:30958899 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases expression multiple interactions |
EXP |
abamectin results in increased expression of STAT3 mRNA Hesperidin inhibits the reaction [abamectin results in increased expression of STAT3 mRNA] |
CTD |
PMID:34748272 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
EXP |
abamectin results in increased expression of TNF mRNA; abamectin results in increased expression of TNF protein [Ascorbic Acid co-treated with Sesame Oil] inhibits the reaction [abamectin results in increased expression of TNF protein]; Ascorbic Acid inhibits the reaction [abamectin results in increased expression of TNF protein]; Hesperidin inhibits the reaction [abamectin results in increased expression of TNF mRNA]; Sesame Oil inhibits the reaction [abamectin results in increased expression of TNF protein] |
CTD |
PMID:31739238 PMID:34748272 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
decreases expression |
ISO |
abamectin results in decreased expression of TUBB3 protein |
CTD |
PMID:19879343 |
|
NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
|
|
|
G |
Arhgef26 |
Rho guanine nucleotide exchange factor 26 |
increases expression |
ISO |
Amphotericin B results in increased expression of ARHGEF26 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 2:146,740,336...146,850,918
Ensembl chr 2:146,739,631...146,850,819
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
Amphotericin B inhibits the reaction [[HIF1A protein binds to ARNT protein] which binds to EPO enhancer] |
CTD |
PMID:16189267 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Atg3 |
autophagy related 3 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of ATG3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr11:55,624,928...55,653,212
Ensembl chr11:55,624,917...55,653,224
|
|
G |
Casp3 |
caspase 3 |
increases expression |
ISO |
Amphotericin B results in increased expression of CASP3 protein |
CTD |
PMID:23988732 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
decreases expression |
EXP |
Amphotericin B results in decreased expression of CAT mRNA |
CTD |
PMID:20623750 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
decreases expression |
EXP |
Amphotericin B results in decreased expression of CCR2 mRNA |
CTD |
PMID:20623750 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Clu |
clusterin |
affects expression |
EXP |
Amphotericin B affects the expression of CLU mRNA |
CTD |
PMID:20623750 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Ednrb |
endothelin receptor type B |
increases expression |
ISO |
Amphotericin B results in increased expression of EDNRB mRNA |
CTD |
PMID:20849824 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Eno1 |
enolase 1 |
multiple interactions |
ISO |
Amphotericin B inhibits the reaction [Oxygen deficiency results in increased expression of ENO1 mRNA]; Amphotericin B results in increased expression of and results in increased secretion of ENO1 protein |
CTD |
PMID:16189267 PMID:26259607 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
ISO |
Amphotericin B inhibits the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to EP300 protein]] |
CTD |
PMID:16189267 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Epo |
erythropoietin |
multiple interactions decreases expression |
ISO EXP |
Amphotericin B inhibits the reaction [[HIF1A protein binds to ARNT protein] which binds to EPO enhancer]; Amphotericin B inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA] Amphotericin B results in decreased expression of EPO protein |
CTD |
PMID:697352 PMID:2299214 PMID:16189267 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Glod4 |
glyoxalase domain containing 4 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of GLOD4 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr10:61,077,535...61,095,876
Ensembl chr10:61,066,421...61,095,898
|
|
G |
Gpr20 |
G protein-coupled receptor 20 |
increases expression |
ISO |
Amphotericin B results in increased expression of GPR20 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 7:105,601,761...105,611,959
Ensembl chr 7:105,602,368...105,603,430
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases expression multiple interactions |
EXP ISO |
Amphotericin B results in decreased expression of GSTP1 mRNA Amphotericin B inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:20623750 PMID:23769903 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
decreases expression |
EXP |
Amphotericin B results in decreased expression of GSTT1 mRNA |
CTD |
PMID:20623750 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases activity |
ISO |
Amphotericin B inhibits the reaction [[HIF1A protein binds to ARNT protein] which binds to EPO enhancer]; Amphotericin B inhibits the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to EP300 protein]]; Amphotericin B promotes the reaction [HIF1AN protein binds to and results in increased hydroxylation of and results in decreased activity of HIF1A protein] Amphotericin B results in decreased activity of HIF1A protein |
CTD |
PMID:16189267 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hif1an |
hypoxia inducible factor 1 subunit alpha inhibitor |
multiple interactions |
ISO |
Amphotericin B promotes the reaction [HIF1AN protein binds to and results in increased hydroxylation of and results in decreased activity of HIF1A protein] |
CTD |
PMID:16189267 |
|
NCBI chr 1:243,419,175...243,440,464
Ensembl chr 1:243,419,194...243,434,327
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
Amphotericin B results in increased expression of and results in increased secretion of HSPA8 protein |
CTD |
PMID:26259607 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Amphotericin B co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Antimony Sodium Gluconate co-treated with Amphotericin B] results in increased expression of IFNG protein |
CTD |
PMID:17911647 PMID:29594315 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ifngr1 |
interferon gamma receptor 1 |
increases expression |
ISO |
Amphotericin B results in increased expression of IFNGR1 |
CTD |
PMID:12803856 |
|
NCBI chr 1:14,333,167...14,351,799
Ensembl chr 1:14,333,187...14,351,785
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of IGFBP5 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[Antimony Sodium Gluconate co-treated with Amphotericin B] results in decreased expression of IL10 protein |
CTD |
PMID:17911647 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Amphotericin B results in increased expression of IL1B mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Amphotericin B co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Kcnq4 |
potassium voltage-gated channel subfamily Q member 4 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of KCNQ4 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 5:134,275,145...134,326,992
Ensembl chr 5:134,275,934...134,326,932
|
|
G |
Lsg1 |
large 60S subunit nuclear export GTPase 1 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of LSG1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr11:70,132,919...70,168,526
Ensembl chr11:70,143,847...70,168,518
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression |
ISO |
Amphotericin B results in increased expression of MAP1LC3B protein |
CTD |
PMID:23988732 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Nprl2 |
NPR2-like, GATOR1 complex subunit |
decreases expression |
ISO |
Amphotericin B results in decreased expression of NPRL2 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 8:108,215,823...108,218,996
Ensembl chr 8:108,215,814...108,218,996
|
|
G |
Nt5c2 |
5'-nucleotidase, cytosolic II |
increases expression |
ISO |
Amphotericin B results in increased expression of NT5C2 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 1:245,770,993...245,896,925
Ensembl chr 1:245,772,277...245,897,913
|
|
G |
Paip1 |
poly(A) binding protein interacting protein 1 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of PAIP1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 2:51,523,142...51,550,241
Ensembl chr 2:51,522,921...51,550,241
|
|
G |
Pard3 |
par-3 family cell polarity regulator |
decreases expression |
ISO |
Amphotericin B results in decreased expression of PARD3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr19:55,080,282...55,630,111
Ensembl chr19:55,080,282...55,629,778
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
multiple interactions |
ISO |
Amphotericin B inhibits the reaction [Oxygen deficiency results in increased expression of PGK1 mRNA] |
CTD |
PMID:16189267 |
|
NCBI chr X:71,271,454...71,287,429
Ensembl chr X:71,271,440...71,287,418
|
|
G |
Polm |
DNA polymerase mu |
increases expression |
ISO |
Amphotericin B results in increased expression of POLM mRNA |
CTD |
PMID:20849824 |
|
NCBI chr14:80,707,075...80,716,677
Ensembl chr14:80,706,345...80,717,086
|
|
G |
RT1-CE5 |
RT1 class I, locus CE5 |
increases expression |
ISO |
Amphotericin B results in increased expression of HLA-F mRNA |
CTD |
PMID:20849824 |
|
NCBI chr20:3,403,418...3,479,476
|
|
G |
Runx3 |
RUNX family transcription factor 3 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of RUNX3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 5:147,393,926...147,419,161
Ensembl chr 5:147,360,994...147,419,156
|
|
G |
Slit1 |
slit guidance ligand 1 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of SLIT1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 1:240,409,559...240,558,127
Ensembl chr 1:240,409,561...240,558,127
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
affects expression |
EXP |
Amphotericin B affects the expression of SPP1 mRNA |
CTD |
PMID:20623750 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Antimony Sodium Gluconate co-treated with Amphotericin B] results in decreased expression of TGFB1 protein |
CTD |
PMID:17911647 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
Amphotericin B results in increased expression of TNF mRNA |
CTD |
PMID:20623750 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
affects expression |
EXP |
Amphotericin B affects the expression of UGT1A9 mRNA |
CTD |
PMID:20623750 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Usp36 |
ubiquitin specific peptidase 36 |
increases expression |
ISO |
Amphotericin B results in increased expression of USP36 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr10:103,497,349...103,528,877
Ensembl chr10:103,497,349...103,528,877
|
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases expression |
ISO |
methylamphotericin B results in increased expression of HAVCR1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
methylamphotericin B results in increased expression of LCN2 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
ISO |
methylamphotericin B results in increased expression of SPP1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
methylamphotericin B results in increased expression of TIMP1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
|
G |
Arg1 |
arginase 1 |
increases expression |
ISO |
Azithromycin results in increased expression of ARG1 protein |
CTD |
PMID:20231397 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Arsa |
arylsulfatase A |
increases activity |
EXP |
Azithromycin results in increased activity of ARSA protein |
CTD |
PMID:8830663 |
|
NCBI chr 7:120,542,788...120,547,577
Ensembl chr 7:120,543,362...120,548,783
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Azithromycin results in decreased expression of CCL2 protein |
CTD |
PMID:20231397 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ctsb |
cathepsin B |
multiple interactions increases activity |
EXP |
Cycloheximide inhibits the reaction [Azithromycin results in increased activity of CTSB protein] |
CTD |
PMID:8830663 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity multiple interactions |
ISO |
Azithromycin results in decreased activity of CYP3A4 protein Azithromycin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone] |
CTD |
PMID:16416302 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Azithromycin results in increased expression of FOS mRNA; Azithromycin results in increased expression of FOS protein |
CTD |
PMID:32454074 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Hexb |
hexosaminidase subunit beta |
increases activity |
EXP |
Azithromycin results in increased activity of HEXB protein |
CTD |
PMID:8830663 |
|
NCBI chr 2:28,483,997...28,504,165
Ensembl chr 2:28,484,012...28,504,223
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO |
Azithromycin results in decreased expression of IL1B protein Azithromycin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Azithromycin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:18435685 PMID:21195124 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
decreases expression |
ISO |
Azithromycin results in decreased expression of IL6 protein |
CTD |
PMID:20231397 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases secretion decreases secretion |
ISO |
Azithromycin results in increased secretion of MMP1 protein Azithromycin results in decreased secretion of MMP1 protein |
CTD |
PMID:24890593 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
increases secretion decreases secretion |
ISO |
Azithromycin results in increased secretion of MMP3 protein Azithromycin results in decreased secretion of MMP3 protein |
CTD |
PMID:24890593 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Pla1a |
phospholipase A1 member A |
increases activity |
EXP |
Azithromycin results in increased activity of PLA1A protein |
CTD |
PMID:8830663 |
|
NCBI chr11:62,320,117...62,357,779
Ensembl chr11:62,320,493...62,357,779
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions |
ISO |
Azithromycin inhibits the reaction [Lipopolysaccharides results in increased activity of RAC1 protein] |
CTD |
PMID:21417583 |
|
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Azithromycin inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression |
ISO |
Azithromycin results in decreased expression of TNF protein |
CTD |
PMID:20231397 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [AGT protein affects the localization of Calcium] |
CTD |
PMID:21613610 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Aim2 |
absent in melanoma 2 |
multiple interactions |
ISO |
[bafilomycin A1 co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of AIM2 protein |
CTD |
PMID:32645460 |
|
NCBI chr13:85,865,206...85,906,996
Ensembl chr13:85,866,284...85,906,975
|
|
G |
Akt1s1 |
AKT1 substrate 1 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein] |
CTD |
PMID:22689575 |
|
NCBI chr 1:95,333,186...95,339,678
Ensembl chr 1:95,332,898...95,339,677
|
|
G |
Alb |
albumin |
decreases uptake |
ISO |
bafilomycin A1 results in decreased uptake of ALB protein |
CTD |
PMID:16313995 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
bafilomycin A1 results in increased expression of APAF1 protein |
CTD |
PMID:28483490 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
multiple interactions |
ISO |
bafilomycin A1 promotes the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased degradation of APPL1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr16:2,118,503...2,166,741
Ensembl chr16:2,121,255...2,166,692
|
|
G |
Asic1 |
acid sensing ion channel subunit 1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Freund's Adjuvant results in increased expression of ASIC1 mRNA] |
CTD |
PMID:16769263 |
|
NCBI chr 7:130,798,317...130,828,535
Ensembl chr 7:130,799,917...130,828,541
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
ATG5 protein affects the reaction [bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]] |
CTD |
PMID:29938581 |
|
NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Hydroxychloroquine results in increased activity of BAX protein] |
CTD |
PMID:12813466 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
bafilomycin A1 results in decreased expression of BCL2 mRNA bafilomycin A1 promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein] |
CTD |
PMID:31310755 PMID:34374793 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Becn1 |
beclin 1 |
multiple interactions increases expression |
ISO EXP |
bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of BECN1 protein] [Swainsonine co-treated with bafilomycin A1] results in increased expression of BECN1 protein; bafilomycin A1 promotes the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of BECN1 protein] bafilomycin A1 results in increased expression of BECN1 protein |
CTD |
PMID:32645460 PMID:33186601 PMID:33242459 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA] |
CTD |
PMID:23111315 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions increases cleavage increases expression |
EXP ISO |
bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein modified form]; bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein] vistusertib affects the reaction [bafilomycin A1 results in increased cleavage of BID protein] bafilomycin A1 results in increased expression of BID protein modified form |
CTD |
PMID:26853465 PMID:28378122 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression multiple interactions |
ISO |
bafilomycin A1 results in increased expression of BNIP3 mRNA; bafilomycin A1 results in increased expression of BNIP3 protein BNIP3 mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; capivasertib affects the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; Erlotinib Hydrochloride inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; Gefitinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; HIF1A mutant form inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; vistusertib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein] |
CTD |
PMID:25981168 PMID:26853465 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Casp3 |
caspase 3 |
decreases activity increases cleavage multiple interactions increases activity |
ISO EXP |
bafilomycin A1 results in decreased activity of CASP3 protein bafilomycin A1 results in increased cleavage of CASP3 protein bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of CASP3 protein] bafilomycin A1 results in increased activity of CASP3 protein [Swainsonine co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [Hydrogen Peroxide results in increased expression of CASP3 protein modified form]; bafilomycin A1 promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein] [bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein; [bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein; [bafilomycin A1 co-treated with methanandamide] results in increased cleavage of CASP3 protein; [Cannabidiol co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; bafilomycin A1 inhibits the reaction [Soot analog results in increased expression of CASP3 protein]; bafilomycin A1 inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [brazilin results in increased activity of CASP3 protein]; bafilomycin A1 promotes the reaction [fosbretabulin results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with methanandamide] results in increased cleavage of CASP3 protein]; vistusertib affects the reaction [bafilomycin A1 results in increased cleavage of CASP3 protein] |
CTD |
PMID:20876807 PMID:23380477 PMID:24321340 PMID:24889822 PMID:25266202 PMID:25981168 PMID:26853465 PMID:28063998 PMID:28378122 PMID:29111403 PMID:30240709 PMID:32708634 PMID:33076330 PMID:33186601 PMID:34374793 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
increases activity |
ISO |
bafilomycin A1 results in increased activity of CASP4 protein |
CTD |
PMID:20371669 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp7 |
caspase 7 |
increases activity decreases activity |
ISO |
bafilomycin A1 results in increased activity of CASP7 protein bafilomycin A1 results in decreased activity of CASP7 protein |
CTD |
PMID:20371669 PMID:25981168 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
EXP ISO |
bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP8 protein] bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of CASP8 protein] |
CTD |
PMID:28378122 PMID:29111403 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP ISO |
bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP9 protein] bafilomycin A1 inhibits the reaction [Soot analog results in increased expression of CASP9 protein] |
CTD |
PMID:28378122 PMID:30240709 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of CCND1 protein] |
CTD |
PMID:33359579 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [xanthatin results in decreased stability of CDC25C protein] |
CTD |
PMID:29074359 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein]; bafilomycin A1 inhibits the reaction [Hydroxychloroquine affects the localization of CTSB protein] |
CTD |
PMID:12813466 PMID:23380477 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [CpG ODN 2216 results in increased expression of CXCL10 protein]; bafilomycin A1 inhibits the reaction [gardiquimod results in increased expression of CXCL10 protein]; bafilomycin A1 inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein] |
CTD |
PMID:26682054 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression multiple interactions |
EXP |
bafilomycin A1 results in increased expression of DDIT4 protein [EGF protein co-treated with bafilomycin A1] results in increased expression of DDIT4 protein |
CTD |
PMID:22689575 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
EXP |
[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine; [bafilomycin A1 co-treated with EGF protein] results in increased abundance of Aspartic Acid; [bafilomycin A1 co-treated with EGF protein] results in increased abundance of Taurine; [EGF protein co-treated with bafilomycin A1] results in increased expression of DDIT4 protein; bafilomycin A1 inhibits the reaction [EGF protein results in increased activity of and results in increased phosphorylation of RPS6KB1 protein]; bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein]; bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine] |
CTD |
PMID:22689575 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Arsenic Trioxide results in decreased expression of EGFR protein] |
CTD |
PMID:30237564 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:22689575 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Epor |
erythropoietin receptor |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Aristolochic Acids results in increased degradation of and results in decreased expression of EPOR protein] |
CTD |
PMID:26136230 |
|
NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO EXP |
bafilomycin A1 inhibits the reaction [FASL protein affects the localization of Calcium] bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of FASLG protein] |
CTD |
PMID:20200208 PMID:28378122 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fmc1 |
formation of mitochondrial complex V assembly factor 1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of FMC1 protein] |
CTD |
PMID:29371327 |
|
NCBI chr 4:67,274,104...67,282,140
Ensembl chr 4:67,274,104...67,282,140
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [resveratrol inhibits the reaction [Hydrogen Peroxide results in increased acetylation of FOXO1 protein]] |
CTD |
PMID:24889822 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression |
ISO |
bafilomycin A1 results in increased expression of GJA1 protein |
CTD |
PMID:35750204 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression multiple interactions |
ISO |
bafilomycin A1 results in increased expression of HIF1A protein HIF1A mutant form inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; HIF1A mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of HIF1A protein] |
CTD |
PMID:25981168 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression multiple interactions |
ISO |
bafilomycin A1 results in decreased expression of HMOX1 protein [bafilomycin A1 co-treated with methanandamide] results in increased expression of HMOX1 protein; [bafilomycin A1 co-treated with tin protoporphyrin IX] promotes the reaction [Cannabidiol results in increased expression of HMOX1 protein]; bafilomycin A1 inhibits the reaction [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole results in increased expression of HMOX1 protein] |
CTD |
PMID:29796178 PMID:33076330 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ifng |
interferon gamma |
decreases expression |
ISO |
bafilomycin A1 results in decreased expression of IFNG mRNA |
CTD |
PMID:16932910 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO |
bafilomycin A1 results in decreased expression of IL1B mRNA [bafilomycin A1 co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of IL1B protein; bafilomycin A1 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein] |
CTD |
PMID:16932910 PMID:24158569 PMID:32645460 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
bafilomycin A1 results in increased expression of IL6 mRNA |
CTD |
PMID:16932910 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
EXP ISO |
bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of EIF4EBP1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of RPS6KB1 protein] bafilomycin A1 promotes the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] |
CTD |
PMID:22689575 PMID:32283200 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
bafilomycin A1 promotes the reaction [pachastrissamine analog promotes the reaction [KEAP1 protein binds to SQSTM1 protein]] |
CTD |
PMID:35123989 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lrrk2 |
leucine-rich repeat kinase 2 |
increases response to substance |
ISO |
LRRK2 gene mutant form results in increased susceptibility to bafilomycin A1 |
CTD |
PMID:25017139 |
|
NCBI chr 7:122,826,712...122,987,711
Ensembl chr 7:122,826,696...122,987,703
|
|
G |
Map1lc3a |
microtubule-associated protein 1 light chain 3 alpha |
multiple interactions increases expression |
ISO |
bafilomycin A1 promotes the reaction [Uranium results in increased expression of MAP1LC3A protein] bafilomycin A1 results in increased expression of MAP1LC3A protein modified form |
CTD |
PMID:30871063 PMID:31120128 |
|
NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases lipidation increases expression increases cleavage decreases degradation |
ISO EXP |
[bafilomycin A1 co-treated with Miconazole] results in increased expression of MAP1LC3B protein; [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone co-treated with bafilomycin A1] results in increased expression of MAP1LC3B mRNA; [TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form; Acetylcysteine inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone promotes the reaction [bafilomycin A1 results in increased expression of MAP1LC3B protein]]; ATG5 protein affects the reaction [bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]]; bafilomycin A1 affects the reaction [Ammonium Chloride results in increased metabolism of MAP1LC3B protein]; bafilomycin A1 affects the reaction [AZD4547 affects the expression of MAP1LC3B protein modified form]; bafilomycin A1 affects the reaction [AZD8186 affects the expression of MAP1LC3B protein modified form]; bafilomycin A1 inhibits the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [[alpha-Chlorohydrin co-treated with Diosgenin] results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [capivasertib results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [Curcumin results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [metarrestin results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [Miconazole results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [Resveratrol results in increased expression of MAP1LC3B protein alternative form]; bafilomycin A1 promotes the reaction [Sevoflurane results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [vistusertib results in increased expression of MAP1LC3B protein modified form]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone promotes the reaction [bafilomycin A1 results in increased expression of MAP1LC3B protein]; Resveratrol promotes the reaction [[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form] bafilomycin A1 results in increased lipidation of MAP1LC3B protein [Doxorubicin co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein; [Glycyrrhizic Acid co-treated with bafilomycin A1] results in increased lipidation of MAP1LC3B protein; bafilomycin A1 promotes the reaction [C1QTNF9 protein results in increased expression of MAP1LC3B protein modified form] bafilomycin A1 results in increased expression of MAP1LC3B protein modified form bafilomycin A1 promotes the reaction [Triiodothyronine results in increased lipidation of MAP1LC3B protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased lipidation of MAP1LC3B protein] bafilomycin A1 results in increased cleavage of MAP1LC3B protein bafilomycin A1 results in decreased degradation of MAP1LC3B protein modified form bafilomycin A1 results in increased expression of MAP1LC3B protein; bafilomycin A1 results in increased expression of MAP1LC3B protein alternative form; bafilomycin A1 results in increased expression of MAP1LC3B protein modified form |
CTD |
PMID:23880069 PMID:24145604 PMID:25301941 PMID:26459185 PMID:26853465 PMID:27305347 PMID:29248574 PMID:29524503 PMID:29908302 PMID:29938581 PMID:30209975 PMID:31310755 PMID:32278738 PMID:32525084 PMID:32981224 PMID:34580807 PMID:34634291 PMID:35149085 PMID:35472370 More...
|
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases expression |
ISO |
bafilomycin A1 inhibits the reaction [Capsaicin results in increased activity of MAPK1 protein]; bafilomycin A1 inhibits the reaction [Iron Compounds results in increased expression of MAPK1 protein modified form]; bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK1 protein] bafilomycin A1 results in increased expression of MAPK1 protein modified form |
CTD |
PMID:20371669 PMID:28483490 PMID:32645460 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases expression |
ISO |
bafilomycin A1 inhibits the reaction [Capsaicin results in increased activity of MAPK3 protein]; bafilomycin A1 inhibits the reaction [Iron Compounds results in increased expression of MAPK3 protein modified form]; bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK3 protein] bafilomycin A1 results in increased expression of MAPK3 protein modified form |
CTD |
PMID:20371669 PMID:28483490 PMID:32645460 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation |
ISO |
bafilomycin A1 results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:31310755 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
bafilomycin A1 results in decreased phosphorylation of MTOR protein |
CTD |
PMID:31310755 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression |
ISO |
bafilomycin A1 results in increased expression of MTTP protein |
CTD |
PMID:34516972 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
multiple interactions |
ISO |
NDRG1 protein results in decreased susceptibility to [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone co-treated with bafilomycin A1] |
CTD |
PMID:24532803 |
|
NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression |
ISO |
bafilomycin A1 promotes the reaction [[Particulate Matter co-treated with Vitamin D] results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [[Silicon Dioxide co-treated with Vitamin D] results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [Particulate Matter results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [Silicon Dioxide results in increased expression of NFE2L2 protein] bafilomycin A1 results in increased expression of NFE2L2 protein |
CTD |
PMID:30698894 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions increases expression |
ISO |
bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of NLRP3 protein] bafilomycin A1 results in increased expression of NLRP3 protein |
CTD |
PMID:32645460 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
decreases expression |
ISO |
bafilomycin A1 results in decreased expression of NR5A1 protein |
CTD |
PMID:29524503 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage increases expression |
ISO EXP |
[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] which results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [brazilin results in increased expression of PARP1 protein modified form]; bafilomycin A1 promotes the reaction [Flavanones results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [fosbretabulin results in increased cleavage of PARP1 protein]; BNIP3 mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; HIF1A mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein] bafilomycin A1 promotes the reaction [Methamphetamine results in increased cleavage of PARP1 protein] bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of PARP1 protein] bafilomycin A1 results in increased expression of PARP1 protein modified form |
CTD |
PMID:20876807 PMID:21616090 PMID:24321340 PMID:25981168 PMID:28063998 PMID:29111403 PMID:31310755 PMID:34374793 PMID:35022897 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of PCNA mRNA] |
CTD |
PMID:33359579 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
bafilomycin A1 affects the localization of and results in increased activity of RELA protein |
CTD |
PMID:10339586 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation multiple interactions |
ISO EXP |
bafilomycin A1 results in decreased phosphorylation of RPS6KB1 protein bafilomycin A1 inhibits the reaction [EGF protein results in increased activity of and results in increased phosphorylation of RPS6KB1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:22689575 PMID:31310755 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA] |
CTD |
PMID:23111315 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [resveratrol inhibits the reaction [Hydrogen Peroxide results in decreased expression of SIRT1 protein]] |
CTD |
PMID:24889822 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc17a7 |
solute carrier family 17 member 7 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [SLC17A7 protein results in increased uptake of Excitatory Amino Acid Agents]; bafilomycin A1 inhibits the reaction [SLC17A7 protein results in increased uptake of Zinc]; bafilomycin A1 inhibits the reaction [SLC30A3 protein promotes the reaction [SLC17A7 protein results in increased uptake of Zinc]] |
CTD |
PMID:15860731 |
|
NCBI chr 1:95,649,709...95,661,591
Ensembl chr 1:95,649,745...95,661,588
|
|
G |
Slc30a3 |
solute carrier family 30 member 3 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [SLC30A3 protein promotes the reaction [SLC17A7 protein results in increased uptake of Zinc]] |
CTD |
PMID:15860731 |
|
NCBI chr 6:25,264,310...25,284,720
Ensembl chr 6:25,275,528...25,284,720
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions increases expression |
ISO |
bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein] bafilomycin A1 results in increased expression of SNAI1 protein |
CTD |
PMID:32645460 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snca |
synuclein alpha |
multiple interactions increases expression |
ISO |
[bafilomycin A1 co-treated with Rotenone] results in increased expression of SNCA protein bafilomycin A1 results in increased expression of SNCA protein |
CTD |
PMID:26031332 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Sort1 |
sortilin 1 |
decreases expression |
ISO |
bafilomycin A1 results in decreased expression of SORT1 protein |
CTD |
PMID:25805502 |
|
NCBI chr 2:195,924,033...196,002,354
Ensembl chr 2:195,924,099...196,002,354
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression multiple interactions |
ISO EXP |
bafilomycin A1 results in increased expression of SQSTM1 protein bafilomycin A1 promotes the reaction [Hydrogen Peroxide results in increased expression of SQSTM1 protein] [Resveratrol co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Silicon Dioxide co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Silicon Dioxide co-treated with Vitamin D co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [TNF protein co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Vitamin D co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [dactolisib results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [pterostilbene inhibits the reaction [Ethanol results in increased expression of SQSTM1 protein]]; bafilomycin A1 inhibits the reaction [Resveratrol results in increased degradation of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Sorafenib results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [metarrestin results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [Miconazole results in increased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [pachastrissamine analog promotes the reaction [KEAP1 protein binds to SQSTM1 protein]]; Fingolimod Hydrochloride affects the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]; sodium arsenite promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein] [bafilomycin A1 co-treated with Rotenone] results in increased expression of SQSTM1 protein; bafilomycin A1 inhibits the reaction [Resveratrol inhibits the reaction [Streptozocin results in increased expression of SQSTM1 protein]]; bafilomycin A1 inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; decamethrin promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]; Streptozocin promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein] |
CTD |
PMID:21778691 PMID:21858812 PMID:23151917 PMID:24145604 PMID:24238063 PMID:24889822 PMID:25939952 PMID:25943029 PMID:26031332 PMID:27305347 PMID:28125038 PMID:29248574 PMID:29524503 PMID:30698894 PMID:32186374 PMID:32645460 PMID:32981224 PMID:33359579 PMID:34405320 PMID:34520793 PMID:34580807 PMID:35123989 More...
|
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tbk1 |
TANK-binding kinase 1 |
multiple interactions |
ISO |
bafilomycin A1 promotes the reaction [Lipopolysaccharides results in increased phosphorylation of TBK1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr 7:57,077,830...57,110,868
Ensembl chr 7:57,077,830...57,110,892
|
|
G |
Tlr8 |
toll-like receptor 8 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [resiquimod results in increased activity of TLR8 protein] |
CTD |
PMID:21398612 |
|
NCBI chr X:27,091,780...27,116,092
Ensembl chr X:27,091,778...27,116,549
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
bafilomycin A1 results in increased expression of TNF mRNA [TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form; [TNF protein co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; resveratrol promotes the reaction [[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form] |
CTD |
PMID:16932910 PMID:24145604 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tomm20 |
translocase of outer mitochondrial membrane 20 |
increases expression multiple interactions |
ISO |
bafilomycin A1 results in increased expression of TOMM20 protein Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of TOMM20 protein] |
CTD |
PMID:30209975 |
|
NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein; bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein] |
CTD |
PMID:23380477 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
EXP |
bafilomycin A1 affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]] |
CTD |
PMID:29128638 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
G |
Usp8 |
ubiquitin specific peptidase 8 |
multiple interactions |
ISO |
[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] which results in increased cleavage of PARP1 protein] |
CTD |
PMID:35022897 |
|
NCBI chr 3:113,962,136...114,009,683
Ensembl chr 3:113,962,164...114,009,666
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions increases expression |
ISO |
Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of VDAC1 protein] |
CTD |
PMID:30209975 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions |
ISO |
[bafilomycin A1 co-treated with Vitamin D] results in increased expression of VDR protein; [Silicon Dioxide co-treated with Vitamin D co-treated with bafilomycin A1] results in increased expression of VDR protein |
CTD |
PMID:30698894 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vim |
vimentin |
multiple interactions increases expression |
ISO |
bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein] bafilomycin A1 results in increased expression of VIM protein |
CTD |
PMID:32645460 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
Brefeldin A inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:15525798 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
EXP |
Brefeldin A inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein] Brefeldin A results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:15525798 PMID:24090963 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
Brefeldin A results in increased expression of ATF4 protein |
CTD |
PMID:24865413 PMID:27358234 PMID:32397857 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO |
Apigenin inhibits the reaction [Brefeldin A results in increased cleavage of ATF6 protein] |
CTD |
PMID:20493918 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atp7a |
ATPase copper transporting alpha |
multiple interactions |
ISO |
Brefeldin A inhibits the reaction [ATP7A protein affects the localization of Doxorubicin] |
CTD |
PMID:17510416 |
|
NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions |
ISO |
Brefeldin A inhibits the reaction [Copper affects the localization of ATP7B protein] |
CTD |
PMID:10982773 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Casp12 |
caspase 12 |
increases activity multiple interactions |
ISO |
Brefeldin A results in increased activity of CASP12 protein Apigenin inhibits the reaction [Brefeldin A results in increased activity of CASP12 protein] |
CTD |
PMID:20493918 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp2 |
caspase 2 |
multiple interactions |
ISO |
Bortezomib promotes the reaction [Brefeldin A results in increased cleavage of and results in increased activity of CASP2 protein]; Brefeldin A promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; Brefeldin A results in increased cleavage of and results in increased activity of CASP2 protein |
CTD |
PMID:18723477 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
Brefeldin A results in increased activity of CASP3 protein Apigenin inhibits the reaction [Brefeldin A results in increased activity of CASP3 protein] |
CTD |
PMID:20150630 PMID:20493918 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cftr |
CF transmembrane conductance regulator |
decreases activity multiple interactions |
ISO |
Brefeldin A results in decreased activity of CFTR protein Brefeldin A inhibits the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium results in increased activity of CFTR protein mutant form]; Brefeldin A inhibits the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [miglustat results in increased activity of CFTR protein mutant form] |
CTD |
PMID:15371258 PMID:18230692 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
Brefeldin A inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; Brefeldin A inhibits the reaction [Quercetin results in increased secretion of CSF2 protein] |
CTD |
PMID:18346843 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
Brefeldin A inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:22167199 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
Brefeldin A results in increased expression of DDIT3 mRNA; Brefeldin A results in increased expression of DDIT3 protein Acetylcysteine inhibits the reaction [Brefeldin A results in increased expression of DDIT3 protein]; Apigenin inhibits the reaction [Brefeldin A results in increased expression of DDIT3 protein]; Glutathione inhibits the reaction [Brefeldin A results in increased expression of DDIT3 protein] |
CTD |
PMID:19428936 PMID:20493918 PMID:20626587 PMID:24865413 PMID:27358234 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases expression |
ISO |
Brefeldin A results in increased expression of EIF2AK3 protein |
CTD |
PMID:24865413 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions increases phosphorylation |
ISO |
Apigenin inhibits the reaction [Brefeldin A results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:20493918 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
multiple interactions |
EXP |
Brefeldin A inhibits the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA] |
CTD |
PMID:17161435 |
|
NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
multiple interactions increases expression |
ISO |
Apigenin inhibits the reaction [Brefeldin A results in increased expression of HSP90B1 protein] |
CTD |
PMID:20493918 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [Brefeldin A results in increased expression of HSPA5 protein]; Apigenin inhibits the reaction [Brefeldin A results in increased expression of HSPA5 protein]; Glutathione inhibits the reaction [Brefeldin A results in increased expression of HSPA5 protein] Brefeldin A results in increased expression of HSPA5 mRNA; Brefeldin A results in increased expression of HSPA5 protein Bortezomib inhibits the reaction [Brefeldin A results in increased expression of HSPA5 protein]; Brefeldin A inhibits the reaction [Shiga toxin subunit A results in increased cleavage of HSPA5 protein] |
CTD |
PMID:12147617 PMID:18723477 PMID:19428936 PMID:20493918 PMID:20626587 PMID:27358234 PMID:32397857 PMID:33483759 More...
|
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Il6 |
interleukin 6 |
decreases secretion multiple interactions |
ISO |
Brefeldin A results in decreased secretion of IL6 protein Brefeldin A inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] |
CTD |
PMID:11216681 PMID:22102721 PMID:24849676 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases expression |
ISO |
Brefeldin A promotes the reaction [vandetanib results in decreased expression of KCNH2 protein modified form] Brefeldin A results in decreased expression of KCNH2 protein modified form |
CTD |
PMID:35680041 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
[aloxistatin co-treated with pepstatin] promotes the reaction [Brefeldin A results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Brefeldin A results in increased expression of and results in increased lipidation of MAP1LC3B protein |
CTD |
PMID:32397857 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation multiple interactions |
EXP |
Brefeldin A results in decreased phosphorylation of MAPK1 protein Brefeldin A inhibits the reaction [Levodopa results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:24090963 PMID:25044243 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions |
EXP |
Brefeldin A results in decreased phosphorylation of MAPK3 protein Brefeldin A inhibits the reaction [Levodopa results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:24090963 PMID:25044243 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nfe2l1 |
NFE2 like bZIP transcription factor 1 |
multiple interactions |
ISO |
Brefeldin A affects the reaction [sodium arsenite affects the localization of NFE2L1 protein] |
CTD |
PMID:20805060 |
|
NCBI chr10:81,796,055...81,812,926
Ensembl chr10:81,800,366...81,832,318
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
Brefeldin A inhibits the reaction [sodium arsenite results in increased activity of NFE2L2 protein] |
CTD |
PMID:20805060 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
decreases expression |
ISO |
Brefeldin A results in decreased expression of NR1I2 mRNA |
CTD |
PMID:25616597 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
Apigenin inhibits the reaction [Brefeldin A results in increased cleavage of PARP1 protein] |
CTD |
PMID:20493918 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Scnn1b |
sodium channel epithelial 1 subunit beta |
multiple interactions |
EXP |
Brefeldin A inhibits the reaction [Terbutaline inhibits the reaction [Oxygen deficiency results in decreased expression of SCNN1B protein]] |
CTD |
PMID:12608646 |
|
NCBI chr 1:176,430,063...176,484,451
Ensembl chr 1:176,430,103...176,484,451
|
|
G |
Scnn1g |
sodium channel epithelial 1 subunit gamma |
multiple interactions |
EXP |
Brefeldin A inhibits the reaction [Terbutaline inhibits the reaction [Oxygen deficiency results in decreased expression of SCNN1G protein]] |
CTD |
PMID:12608646 |
|
NCBI chr 1:176,304,942...176,338,816
Ensembl chr 1:176,304,942...176,338,816
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion |
ISO |
Brefeldin A results in decreased secretion of TNF protein |
CTD |
PMID:22102721 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
multiple interactions |
ISO |
Brefeldin A inhibits the reaction [Bortezomib results in increased localization of TNFRSF10A protein] |
CTD |
PMID:17326159 |
|
NCBI chr15:44,839,818...44,867,582
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
Brefeldin A affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] |
CTD |
PMID:17326159 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
increases expression |
ISO |
Brefeldin A results in increased expression of TP53BP1 protein |
CTD |
PMID:27358234 |
|
NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases secretion multiple interactions increases expression |
ISO |
Brefeldin A results in decreased secretion of VEGFA protein Brefeldin A inhibits the reaction [cobaltous chloride results in increased secretion of VEGFA protein] Brefeldin A results in increased expression of VEGFA mRNA |
CTD |
PMID:12147617 PMID:20850416 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions increases expression increases activity |
ISO |
bortezomib inhibits the reaction [Brefeldin A results in increased activity of XBP1 protein] Brefeldin A results in increased expression of XBP1 protein |
CTD |
PMID:18723477 PMID:27358234 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Clarithromycin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Clarithromycin results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
increases expression |
ISO |
Clarithromycin results in increased expression of ASAH1 mRNA |
CTD |
PMID:15342952 |
|
NCBI chr16:50,966,404...50,997,827
Ensembl chr16:50,966,229...51,008,233
|
|
G |
Cept1 |
choline/ethanolamine phosphotransferase 1 |
decreases expression |
ISO |
Clarithromycin results in decreased expression of CEPT1 mRNA |
CTD |
PMID:34458952 |
|
NCBI chr 2:193,994,220...194,036,141
Ensembl chr 2:193,993,447...194,035,578
|
|
G |
Ch25h |
cholesterol 25-hydroxylase |
increases expression |
ISO |
Clarithromycin results in increased expression of CH25H mRNA |
CTD |
PMID:34458952 |
|
NCBI chr 1:232,014,877...232,016,195
Ensembl chr 1:232,014,880...232,016,195
|
|
G |
Chpt1 |
choline phosphotransferase 1 |
decreases expression |
ISO |
Clarithromycin results in decreased expression of CHPT1 mRNA |
CTD |
PMID:34458952 |
|
NCBI chr 7:22,866,455...22,915,111
Ensembl chr 7:22,863,027...22,915,103
|
|
G |
Ckm |
creatine kinase, M-type |
multiple interactions |
ISO |
[Clarithromycin co-treated with Simvastatin] results in increased expression of CKM protein |
CTD |
PMID:19252767 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Ofloxacin co-treated with Clarithromycin] inhibits the reaction [CYP1A2 protein results in increased metabolism of Theophylline] |
CTD |
PMID:11408986 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity multiple interactions decreases expression |
ISO |
Clarithromycin results in decreased activity of CYP3A4 protein [Ofloxacin co-treated with Clarithromycin] inhibits the reaction [CYP3A4 protein results in increased metabolism of Theophylline]; Clarithromycin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]; Clarithromycin inhibits the reaction [CYP3A4 protein results in increased metabolism of Disopyramide] Clarithromycin results in decreased expression of CYP3A4 mRNA |
CTD |
PMID:10234723 PMID:11408986 PMID:16416302 PMID:16837568 PMID:23748747 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Clarithromycin results in increased expression of FOS mRNA; Clarithromycin results in increased expression of FOS protein |
CTD |
PMID:32454074 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP ISO |
[IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Clarithromycin |
CTD |
PMID:19362101 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO EXP |
[IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Clarithromycin; [IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Clarithromycin |
CTD |
PMID:19362101 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
ISO |
Clarithromycin results in decreased expression of IL4 protein |
CTD |
PMID:16006447 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO EXP |
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Clarithromycin Clarithromycin results in decreased expression of IL6 mRNA |
CTD |
PMID:9869567 PMID:19362101 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inhbe |
inhibin subunit beta E |
increases expression |
ISO |
Clarithromycin results in increased expression of INHBE mRNA |
CTD |
PMID:15342952 |
|
NCBI chr 7:63,177,558...63,178,983
Ensembl chr 7:63,176,219...63,179,172
|
|
G |
Itgb4 |
integrin subunit beta 4 |
decreases expression |
ISO |
Clarithromycin results in decreased expression of ITGB4 protein |
CTD |
PMID:14687228 |
|
NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012
|
|
G |
Kcne2 |
potassium voltage-gated channel subfamily E regulatory subunit 2 |
multiple interactions |
ISO |
[KCNE2 protein mutant form binds to KCNH2 protein] which results in increased susceptibility to Clarithromycin |
CTD |
PMID:10219239 |
|
NCBI chr11:31,517,176...31,530,026
Ensembl chr11:31,295,614...31,530,043
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
[KCNE2 protein mutant form binds to KCNH2 protein] which results in increased susceptibility to Clarithromycin Clarithromycin results in decreased activity of KCNH2 protein |
CTD |
PMID:10219239 PMID:24052561 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Lss |
lanosterol synthase |
decreases expression |
ISO |
Clarithromycin results in decreased expression of LSS mRNA |
CTD |
PMID:15342952 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression |
EXP |
Clarithromycin results in decreased expression of MMP9 mRNA |
CTD |
PMID:9869567 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
decreases expression |
ISO |
Clarithromycin results in decreased expression of COX2 protein |
CTD |
PMID:31915244 |
|
NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Mtif2 |
mitochondrial translational initiation factor 2 |
decreases response to substance |
ISO |
MTIF2 protein results in decreased susceptibility to Clarithromycin |
CTD |
PMID:31915244 |
|
NCBI chr14:103,265,808...103,285,733
Ensembl chr14:103,270,039...103,285,728
|
|
G |
Phyh |
phytanoyl-CoA 2-hydroxylase |
decreases expression |
ISO |
Clarithromycin results in decreased expression of PHYH mRNA |
CTD |
PMID:15342952 |
|
NCBI chr17:73,329,461...73,346,359
Ensembl chr17:73,329,082...73,346,409
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
Clarithromycin inhibits the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein] |
CTD |
PMID:21430235 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Sv2a |
synaptic vesicle glycoprotein 2a |
decreases expression |
ISO |
Clarithromycin results in decreased expression of SV2A mRNA |
CTD |
PMID:34458952 |
|
NCBI chr 2:183,741,455...183,757,290
Ensembl chr 2:183,741,547...183,756,927
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
[IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Clarithromycin; [IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Clarithromycin Clarithromycin results in decreased expression of TNF mRNA |
CTD |
PMID:9869567 PMID:19362101 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
concanamycin A inhibits the reaction [enterotoxin C, staphylococcal results in increased expression of BAX protein] |
CTD |
PMID:27742270 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression multiple interactions |
ISO |
concanamycin A results in increased expression of BNIP3 mRNA lapatinib inhibits the reaction [concanamycin A results in increased expression of BNIP3 mRNA] |
CTD |
PMID:25981168 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
concanamycin A inhibits the reaction [enterotoxin C, staphylococcal analog results in increased activity of CASP3 protein]; concanamycin A inhibits the reaction [enterotoxin C, staphylococcal results in increased activity of CASP3 protein] |
CTD |
PMID:27742270 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
concanamycin A inhibits the reaction [enterotoxin C, staphylococcal analog results in increased activity of CASP9 protein]; concanamycin A inhibits the reaction [enterotoxin C, staphylococcal results in increased activity of CASP9 protein] |
CTD |
PMID:27742270 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
concanamycin A results in increased expression of F3 protein |
CTD |
PMID:25569083 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression multiple interactions |
ISO |
concanamycin A results in increased expression of HIF1A protein lapatinib inhibits the reaction [concanamycin A results in increased expression of HIF1A protein] |
CTD |
PMID:25981168 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[lapatinib co-treated with concanamycin A] results in increased cleavage of PARP1 protein |
CTD |
PMID:25981168 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases activity multiple interactions |
ISO |
emamectin results in decreased activity of ABCB1 protein emamectin inhibits the reaction [ABCB1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride] emamectin results in decreased activity of ABCB1A protein emamectin inhibits the reaction [ABCB1A protein results in increased transport of bisbenzimide ethoxide trihydrochloride] |
CTD |
PMID:25865432 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions decreases activity |
ISO |
emamectin inhibits the reaction [ABCC1 protein results in increased transport of bisbenzimide ethoxide trihydrochloride] emamectin results in decreased activity of ABCC1 protein |
CTD |
PMID:25865432 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
emamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]] |
CTD |
PMID:27773686 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
emamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; emamectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; emamectin inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 PMID:27773686 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
ISO |
Plant Oils inhibits the reaction [emamectin benzoate results in decreased activity of CAT protein] |
CTD |
PMID:29268245 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions increases expression |
ISO |
Plant Oils inhibits the reaction [emamectin benzoate results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:29268245 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases activity |
ISO |
emamectin benzoate results in decreased activity of DIO1 protein |
CTD |
PMID:29228274 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
increases expression multiple interactions |
ISO |
emamectin benzoate results in increased expression of MGST1 mRNA Plant Oils inhibits the reaction [emamectin benzoate results in increased expression of MGST1 mRNA] |
CTD |
PMID:29268245 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Nts |
neurotensin |
affects activity |
ISO |
emamectin benzoate affects the activity of NTS protein |
CTD |
PMID:23611293 |
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Erythromycin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Erythromycin results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions affects transport |
ISO EXP |
Erythromycin inhibits the reaction [ABCB1 protein results in increased secretion of Vinblastine]; Erythromycin inhibits the reaction [ABCB1 protein results in increased transport of quinidinium] ABCB1 protein affects the transport of Erythromycin |
CTD |
PMID:12235267 PMID:15304119 PMID:25268938 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions increases expression |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of ACACA mRNA Erythromycin results in increased expression of ACACA mRNA |
CTD |
PMID:27503388 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acly |
ATP citrate lyase |
increases expression multiple interactions |
ISO |
Erythromycin results in increased expression of ACLY mRNA [Penicillin G co-treated with Erythromycin] results in increased expression of ACLY mRNA |
CTD |
PMID:27503388 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
increases expression |
ISO |
Erythromycin results in increased expression of ASAH1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr16:50,966,404...50,997,827
Ensembl chr16:50,966,229...51,008,233
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
decreases expression |
ISO |
Erythromycin results in decreased expression of ASNS mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
[Erythromycin co-treated with IL1B protein] results in increased activity of CASP3 protein; [Erythromycin co-treated with IL6 protein] results in increased activity of CASP3 protein; [Erythromycin co-treated with TNF protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] inhibits the reaction [Erythromycin results in increased activity of CASP3 protein] |
CTD |
PMID:30876886 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[Benzoyl Peroxide co-treated with Erythromycin] results in decreased activity of CAT protein |
CTD |
PMID:11809596 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
Erythromycin results in increased expression of CCL2 mRNA [Penicillin G co-treated with Erythromycin] results in increased expression of CCL2 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression multiple interactions |
ISO |
Erythromycin results in increased expression of CCR2 mRNA [Penicillin G co-treated with Erythromycin] results in increased expression of CCR2 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Cd34 |
CD34 molecule |
increases expression |
ISO |
Erythromycin results in increased expression of CD34 protein |
CTD |
PMID:16297520 |
|
NCBI chr13:106,480,074...106,499,462
Ensembl chr13:106,480,043...106,499,832
|
|
G |
Cd36 |
CD36 molecule |
increases expression multiple interactions |
ISO |
Erythromycin results in increased expression of CD36 mRNA [Penicillin G co-treated with Erythromycin] results in increased expression of CD36 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions increases expression |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of CPT1A mRNA Erythromycin results in increased expression of CPT1A mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Crp |
C-reactive protein |
increases expression multiple interactions |
ISO |
Erythromycin results in increased expression of CRP mRNA [Penicillin G co-treated with Erythromycin] results in increased expression of CRP mRNA |
CTD |
PMID:27503388 |
|
NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cs |
citrate synthase |
increases expression multiple interactions |
ISO |
Erythromycin results in increased expression of CS mRNA [Penicillin G co-treated with Erythromycin] results in increased expression of CS mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
increases expression |
ISO |
Erythromycin results in increased expression of CXCR4 protein |
CTD |
PMID:19502290 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
increases expression |
ISO |
Erythromycin results in increased expression of CYP11B2 |
CTD |
PMID:17822730 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity |
ISO |
Erythromycin results in decreased activity of CYP2C29 protein |
CTD |
PMID:18420780 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity |
ISO |
Erythromycin results in decreased activity of CYP2D22 protein |
CTD |
PMID:18420780 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases methylation increases metabolic processing affects metabolic processing decreases activity increases expression multiple interactions |
ISO |
CYP3A4 protein results in decreased methylation of Erythromycin CYP3A4 protein results in increased metabolism of Erythromycin CYP3A4 protein affects the metabolism of Erythromycin Erythromycin results in decreased activity of CYP3A4 protein Erythromycin results in increased expression of CYP3A4 mRNA; Erythromycin results in increased expression of CYP3A4 protein Erythromycin inhibits the reaction [CYP3A4 protein affects the metabolism of brotizolam]; Erythromycin inhibits the reaction [CYP3A4 protein results in decreased methylation of Etoposide]; Erythromycin inhibits the reaction [CYP3A4 protein results in decreased methylation of Teniposide]; Erythromycin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]; Erythromycin inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]; IFNA protein inhibits the reaction [CYP3A4 protein results in increased metabolism of Erythromycin] |
CTD |
PMID:2271712 PMID:8114683 PMID:15383492 PMID:15466163 PMID:15845683 PMID:16041596 PMID:16042670 PMID:16416302 PMID:18505790 PMID:19299527 PMID:21466820 More...
|
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
decreases methylation |
ISO |
CYP3A5 protein results in decreased methylation of Erythromycin |
CTD |
PMID:15383492 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Defb1 |
defensin beta 1 |
decreases expression multiple interactions |
ISO |
Erythromycin results in decreased expression of DEFB1 mRNA [Penicillin G co-treated with Erythromycin] results in decreased expression of DEFB1 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr16:70,298,862...70,313,604
Ensembl chr16:70,298,863...70,313,604
|
|
G |
Depp1 |
DEPP autophagy regulator 1 |
increases expression |
ISO |
Erythromycin results in increased expression of DEPP1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of DGAT1 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of DGAT2 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
increases expression multiple interactions |
ISO |
Erythromycin results in increased expression of FABP1 mRNA [Penicillin G co-treated with Erythromycin] results in increased expression of FABP1 mRNA |
CTD |
PMID:17175557 PMID:27503388 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fasn |
fatty acid synthase |
increases expression multiple interactions |
ISO |
Erythromycin results in increased expression of FASN mRNA [Penicillin G co-treated with Erythromycin] results in increased expression of FASN mRNA |
CTD |
PMID:27503388 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fndc4 |
fibronectin type III domain containing 4 |
decreases expression |
ISO |
Erythromycin results in decreased expression of FNDC4 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 6:25,077,155...25,080,812
Ensembl chr 6:25,077,349...25,080,675
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Erythromycin results in increased expression of FOS mRNA; Erythromycin results in increased expression of FOS protein |
CTD |
PMID:32454074 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
increases expression multiple interactions |
ISO |
Erythromycin results in increased expression of GPAM mRNA [Penicillin G co-treated with Erythromycin] results in increased expression of GPAM mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Erythromycin inhibits the reaction [Particulate Matter results in increased expression of HMOX1 mRNA]; Erythromycin inhibits the reaction [Vehicle Emissions results in increased expression of HMOX1 mRNA] |
CTD |
PMID:23291319 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hpn |
hepsin |
increases expression |
ISO |
Erythromycin results in increased expression of HPN mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 1:86,337,085...86,352,785
Ensembl chr 1:86,337,087...86,352,811
|
|
G |
Hrh1 |
histamine receptor H 1 |
multiple interactions |
EXP |
[Diphenhydramine results in decreased activity of HRH1 protein] which results in decreased susceptibility to Erythromycin |
CTD |
PMID:12856827 |
|
NCBI chr 4:147,564,781...147,649,353
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
Erythromycin results in increased expression of ICAM1 protein |
CTD |
PMID:14729754 PMID:16297520 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions increases expression |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of IFNG mRNA Erythromycin results in increased expression of IFNG mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression multiple interactions |
ISO |
Erythromycin results in increased expression of IL1A mRNA [Penicillin G co-treated with Erythromycin] results in increased expression of IL1A mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Erythromycin co-treated with IL1B protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] inhibits the reaction [Erythromycin results in increased activity of CASP3 protein] |
CTD |
PMID:30876886 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
Erythromycin results in increased expression of IL6 mRNA [Erythromycin co-treated with IL6 protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] inhibits the reaction [Erythromycin results in increased activity of CASP3 protein] [Penicillin G co-treated with Erythromycin] results in increased expression of IL6 mRNA |
CTD |
PMID:27503388 PMID:30876886 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inhbe |
inhibin subunit beta E |
increases expression |
ISO |
Erythromycin results in increased expression of INHBE mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 7:63,177,558...63,178,983
Ensembl chr 7:63,176,219...63,179,172
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects binding decreases activity multiple interactions |
ISO |
Erythromycin binds to KCNH2 protein Erythromycin results in decreased activity of KCNH2 protein Erythromycin affects the reaction [KCNH2 protein results in decreased susceptibility to Doxorubicin]; Erythromycin binds to and results in decreased activity of KCNH2 protein |
CTD |
PMID:15272206 PMID:16086867 PMID:18701618 PMID:24052561 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Lbp |
lipopolysaccharide binding protein |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of LBP mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586
|
|
G |
Lss |
lanosterol synthase |
increases expression |
ISO |
Erythromycin results in increased expression of LSS mRNA |
CTD |
PMID:17175557 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of MTTP mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Muc2 |
mucin 2, oligomeric mucus/gel-forming |
decreases expression multiple interactions |
ISO |
Erythromycin results in decreased expression of MUC2 mRNA [Penicillin G co-treated with Erythromycin] results in decreased expression of MUC2 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 1:196,796,257...196,831,740
Ensembl chr 1:196,799,517...196,831,756
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
Erythromycin inhibits the reaction [Particulate Matter results in increased activity of NFE2L2 protein]; Erythromycin inhibits the reaction [Vehicle Emissions results in increased activity of NFE2L2 protein] |
CTD |
PMID:23291319 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression multiple interactions |
ISO |
Erythromycin results in increased expression of NFKB1 mRNA [Penicillin G co-treated with Erythromycin] results in increased expression of NFKB1 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
Erythromycin inhibits the reaction [Particulate Matter results in increased expression of NQO1 mRNA]; Erythromycin inhibits the reaction [Vehicle Emissions results in increased expression of NQO1 mRNA] |
CTD |
PMID:23291319 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
increases expression decreases expression |
ISO |
Erythromycin results in increased expression of NUPR1 mRNA Erythromycin results in decreased expression of NUPR1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 1:181,213,292...181,215,327
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
decreases expression |
ISO |
Erythromycin results in decreased expression of PLA2G2A mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Reg3g |
regenerating family member 3 gamma |
multiple interactions decreases expression |
ISO |
[Penicillin G co-treated with Erythromycin] results in decreased expression of REG3G mRNA Erythromycin results in decreased expression of REG3G mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 4:110,922,805...110,927,803
Ensembl chr 4:110,924,168...110,926,723
|
|
G |
Retnlb |
resistin like beta |
multiple interactions decreases expression |
ISO |
[Penicillin G co-treated with Erythromycin] results in decreased expression of RETNLB mRNA Erythromycin results in decreased expression of RETNLB mRNA |
CTD |
PMID:27503388 |
|
NCBI chr11:51,983,482...51,985,368
Ensembl chr11:51,983,483...51,985,368
|
|
G |
RT1-M3-1 |
RT1 class Ib, locus M3, gene 1 |
affects expression |
ISO |
Erythromycin affects the expression of HLA-G mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions increases expression |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of SCD1 mRNA Erythromycin results in increased expression of SCD1 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Sele |
selectin E |
increases expression |
ISO |
Erythromycin results in increased expression of SELE protein |
CTD |
PMID:16297520 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Sell |
selectin L |
increases expression |
ISO |
Erythromycin results in increased expression of SELL protein |
CTD |
PMID:16297520 |
|
NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
multiple interactions |
ISO |
Erythromycin inhibits the reaction [SLC22A7 protein results in increased transport of Tetracycline] Erythromycin inhibits the reaction [SLC22A7 protein results in increased uptake of Glutarates] |
CTD |
PMID:12065749 PMID:15901346 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slc27a2 |
solute carrier family 27 member 2 |
multiple interactions |
ISO |
[Penicillin G co-treated with Erythromycin] results in increased expression of SLC27A2 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
increases expression multiple interactions |
ISO |
Erythromycin results in increased expression of SREBF1 mRNA [Penicillin G co-treated with Erythromycin] results in increased expression of SREBF1 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tagln |
transgelin |
decreases expression |
ISO |
Erythromycin results in decreased expression of TAGLN mRNA |
CTD |
PMID:17567588 |
|
NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
|
|
G |
Tlr4 |
toll-like receptor 4 |
increases expression multiple interactions |
ISO |
Erythromycin results in increased expression of TLR4 mRNA [Penicillin G co-treated with Erythromycin] results in increased expression of TLR4 mRNA |
CTD |
PMID:27503388 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
Erythromycin results in increased expression of TNF mRNA [Erythromycin co-treated with TNF protein] results in increased activity of CASP3 protein; [TNF protein co-treated with IL6 protein co-treated with IL1B protein] inhibits the reaction [Erythromycin results in increased activity of CASP3 protein] [Penicillin G co-treated with Erythromycin] results in increased expression of TNF mRNA |
CTD |
PMID:27503388 PMID:30876886 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression |
ISO |
Erythromycin results in increased expression of VCAM1 protein |
CTD |
PMID:16297520 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Wipi1 |
WD repeat domain, phosphoinositide interacting 1 |
increases expression |
ISO |
Erythromycin results in increased expression of WIPI1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr10:94,542,946...94,580,174
Ensembl chr10:94,542,946...94,579,846
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression decreases activity |
EXP ISO |
Erythromycin Estolate results in decreased expression of ABCB11 mRNA Erythromycin Estolate results in decreased activity of ABCB11 protein |
CTD |
PMID:17522070 PMID:20829430 PMID:23956101 PMID:28437613 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of ABCB1 mRNA; Erythromycin Estolate results in increased expression of ABCB1A mRNA |
CTD |
PMID:17522070 PMID:24412560 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of ABCC3 mRNA |
CTD |
PMID:17522070 PMID:24412560 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of ABCG5 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of ABCG8 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of ACADM mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acly |
ATP citrate lyase |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of ACLY mRNA |
CTD |
PMID:17522070 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of ACSL1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase 3 family, member A2 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of ALDH3A2 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of APEX1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Aspm |
assembly factor for spindle microtubules |
decreases expression increases expression |
EXP |
Erythromycin Estolate results in decreased expression of ASPM mRNA Erythromycin Estolate results in increased expression of ASPM mRNA |
CTD |
PMID:24412560 |
|
NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755
|
|
G |
Aurkb |
aurora kinase B |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of AURKB mRNA Erythromycin Estolate results in decreased expression of AURKB mRNA |
CTD |
PMID:24412560 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of BAX mRNA |
CTD |
PMID:12883083 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of BCL2 mRNA |
CTD |
PMID:12883083 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of BTG2 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of CACNA1I mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688
|
|
G |
Calu |
calumenin |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of CALU mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of CAR1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208
|
|
G |
Cat |
catalase |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of CAT mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of CCN2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccna2 |
cyclin A2 |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of CCNA2 mRNA Erythromycin Estolate results in decreased expression of CCNA2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression increases expression |
EXP |
Erythromycin Estolate results in decreased expression of CCNB1 mRNA Erythromycin Estolate results in increased expression of CCNB1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cdca3 |
cell division cycle associated 3 |
decreases expression increases expression |
EXP |
Erythromycin Estolate results in decreased expression of CDCA3 mRNA Erythromycin Estolate results in increased expression of CDCA3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of CDK1 mRNA Erythromycin Estolate results in decreased expression of CDK1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of CEACAM1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Cenpw |
centromere protein W |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of CENPW mRNA Erythromycin Estolate results in decreased expression of CENPW mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:27,525,324...27,530,464
Ensembl chr 1:27,525,324...27,530,464
|
|
G |
Ces2h |
carboxylesterase 2H |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of CES2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Chd2 |
chromodomain helicase DNA binding protein 2 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of CHD2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502
|
|
G |
Ctsl |
cathepsin L |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of CTSL mRNA |
CTD |
PMID:17522070 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cyb5r3 |
cytochrome b5 reductase 3 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of CYB5R3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of CYP1A1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of CYP2D3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:113,917,711...113,922,068
Ensembl chr 7:113,908,947...113,922,084
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:12883083 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of CYP3A9 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of CYP8B1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of DDIT3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dut |
deoxyuridine triphosphatase |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of DUT mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:112,498,864...112,509,994
Ensembl chr 3:112,498,982...112,510,771
|
|
G |
Ect2 |
epithelial cell transforming 2 |
decreases expression increases expression |
EXP |
Erythromycin Estolate results in decreased expression of ECT2 mRNA Erythromycin Estolate results in increased expression of ECT2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:109,975,813...110,037,911
Ensembl chr 2:109,975,813...110,037,911
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of FABP1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fads1 |
fatty acid desaturase 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of FADS1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Fam111a |
FAM111 trypsin like peptidase A |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of FAM111A mRNA Erythromycin Estolate results in decreased expression of FAM111A mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:209,640,865...209,656,551
Ensembl chr 1:209,640,953...209,656,547
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of FASN mRNA |
CTD |
PMID:17522070 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fga |
fibrinogen alpha chain |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of FGA mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:168,365,364...168,381,533
Ensembl chr 2:168,374,120...168,381,528
|
|
G |
Fgb |
fibrinogen beta chain |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of FGB mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of FMO1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of G6PC1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of GADD45A mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gck |
glucokinase |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of GCK mRNA |
CTD |
PMID:17522070 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of GPX1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of GPX2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of GSTM3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:195,531,627...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Hibadh |
3-hydroxyisobutyrate dehydrogenase |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of HIBADH mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:81,649,180...81,747,244
Ensembl chr 4:81,649,175...81,780,617
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of HMMR mRNA Erythromycin Estolate results in decreased expression of HMMR mRNA |
CTD |
PMID:24412560 |
|
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
|
|
G |
Igf2r |
insulin-like growth factor 2 receptor |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of IGF2R mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:47,979,109...48,067,501
Ensembl chr 1:47,979,109...48,067,501
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of IGFBP1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of IGFBP2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Ip6k2 |
inositol hexakisphosphate kinase 2 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of IP6K2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 8:109,483,843...109,510,172
Ensembl chr 8:109,484,310...109,510,166
|
|
G |
Isy1 |
ISY1 splicing factor homolog |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of ISY1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 4:120,276,535...120,297,227
Ensembl chr 4:120,276,292...120,297,188
|
|
G |
Kif20b |
kinesin family member 20B |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of KIF20B mRNA Erythromycin Estolate results in decreased expression of KIF20B mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:232,428,293...232,483,798
Ensembl chr 1:232,428,371...232,483,787
|
|
G |
Kif23 |
kinesin family member 23 |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of KIF23 mRNA Erythromycin Estolate results in decreased expression of KIF23 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072
|
|
G |
Kif2c |
kinesin family member 2C |
decreases expression increases expression |
EXP |
Erythromycin Estolate results in decreased expression of KIF2C mRNA Erythromycin Estolate results in increased expression of KIF2C mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637
|
|
G |
Krt18 |
keratin 18 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of KRT18 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
|
|
G |
Lbp |
lipopolysaccharide binding protein |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of LBP mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586
|
|
G |
Lgals3 |
galectin 3 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of LGALS3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025
|
|
G |
Lipc |
lipase C, hepatic type |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of LIPC mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lpin1 |
lipin 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of LPIN1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of LPL mRNA |
CTD |
PMID:17522070 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Maob |
monoamine oxidase B |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of MAOB mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Mir16 |
microRNA 16 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of MIR16 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:153,245,349...153,245,443
Ensembl chr 2:153,245,349...153,245,443
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of MYC mRNA Erythromycin Estolate results in decreased expression of MYC mRNA |
CTD |
PMID:17522070 PMID:24412560 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Ncaph |
non-SMC condensin I complex, subunit H |
decreases expression increases expression |
EXP |
Erythromycin Estolate results in decreased expression of NCAPH mRNA Erythromycin Estolate results in increased expression of NCAPH mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:114,371,937...114,399,223
Ensembl chr 3:114,371,941...114,399,180
|
|
G |
Nfkbib |
NFKB inhibitor beta |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of NFKBIB mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Noct |
nocturnin |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of NOCT mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:135,271,189...135,291,400
|
|
G |
Nusap1 |
nucleolar and spindle associated protein 1 |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of NUSAP1 mRNA Erythromycin Estolate results in decreased expression of NUSAP1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:106,603,273...106,633,624
Ensembl chr 3:106,603,289...106,633,624
|
|
G |
Obp3 |
alpha-2u globulin PGCL4 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of OBP3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 5:74,842,316...74,845,858
Ensembl chr 5:74,842,316...74,845,757
|
|
G |
Otc |
ornithine transcarbamylase |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of OTC mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:12,453,834...12,529,954
Ensembl chr X:12,453,834...12,566,918
|
|
G |
Pclaf |
PCNA clamp associated factor |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of PCLAF mRNA Erythromycin Estolate results in decreased expression of PCLAF mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 8:66,420,673...66,432,568
Ensembl chr 8:66,420,587...66,432,994 Ensembl chr 8:66,420,587...66,432,994
|
|
G |
Pcmtd1 |
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of PCMTD1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 5:12,284,711...12,355,680
Ensembl chr 5:12,284,711...12,354,899
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of PDK4 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Per1 |
period circadian regulator 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of PER1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431
|
|
G |
Pfkfb3 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of PFKFB3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr17:66,983,629...67,064,702
Ensembl chr17:66,983,686...67,063,125
|
|
G |
Pklr |
pyruvate kinase L/R |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of PKLR mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
|
|
G |
Pygl |
glycogen phosphorylase L |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of PYGL mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310
|
|
G |
Rad51 |
RAD51 recombinase |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of RAD51 mRNA Erythromycin Estolate results in decreased expression of RAD51 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
decreases expression increases expression |
EXP |
Erythromycin Estolate results in decreased expression of RRM2 mRNA Erythromycin Estolate results in increased expression of RRM2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of S100A8 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of S100A9 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Serpina7 |
serpin family A member 7 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of SERPINA7 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr X:102,663,242...102,722,319
Ensembl chr X:102,663,405...102,669,040
|
|
G |
Sertad3 |
SERTA domain containing 3 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of SERTAD3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:82,763,535...82,767,271
Ensembl chr 1:82,763,149...82,769,001
|
|
G |
Shcbp1 |
SHC binding and spindle associated 1 |
decreases expression increases expression |
EXP |
Erythromycin Estolate results in decreased expression of SHCBP1 mRNA Erythromycin Estolate results in increased expression of SHCBP1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr16:84,672,276...84,703,839
Ensembl chr16:84,672,321...84,703,844
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of SLC38A2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of SLCO1A4 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of SLCO1B2 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Spc25 |
SPC25 component of NDC80 kinetochore complex |
increases expression decreases expression |
EXP |
Erythromycin Estolate results in increased expression of SPC25 mRNA Erythromycin Estolate results in decreased expression of SPC25 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:53,930,013...53,988,940
Ensembl chr 3:53,975,704...53,988,959
|
|
G |
Spin2b |
spindlin family member 2B |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of SPIN2B mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:17,190,371...17,192,351
Ensembl chr X:17,180,474...17,192,351
|
|
G |
Spink1 |
serine peptidase inhibitor, Kazal type 1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of SPINK1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr18:35,870,723...35,882,693
Ensembl chr18:35,824,550...35,882,642
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of SREBF1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of STAT3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Styxl1 |
serine/threonine/tyrosine interacting-like 1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of STYXL1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr12:20,907,410...20,940,232
Ensembl chr12:20,907,435...20,939,752
|
|
G |
Sugt1 |
SGT1 homolog, MIS12 kinetochore complex assembly cochaperone |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of SUGT1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr15:54,991,419...55,032,244
Ensembl chr15:54,990,672...55,069,150
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of TGFB3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564
|
|
G |
Thrsp |
thyroid hormone responsive |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of THRSP mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of TIMP1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tmcc1 |
transmembrane and coiled-coil domain family 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of TMCC1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 4:149,069,252...149,239,585
Ensembl chr 4:149,069,260...149,239,620
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of TNFAIP3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of TNFRSF1A mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of TP53 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tsc22d3 |
TSC22 domain family, member 3 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of TSC22D3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr X:104,217,898...104,277,935
Ensembl chr X:104,217,925...104,276,861
|
|
G |
Ttr |
transthyretin |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of TTR mRNA |
CTD |
PMID:17522070 |
|
NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of TXNRD1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Ugt2a1 |
UDP glucuronosyltransferase family 2 member A1 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of UGT2A1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr14:20,521,018...20,545,060
Ensembl chr14:20,517,951...20,545,531
|
|
G |
Zc3h13 |
zinc finger CCCH type containing 13 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of ZC3H13 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr15:50,607,335...50,671,802
Ensembl chr15:50,607,380...50,671,802
|
|
G |
Zfp354a |
zinc finger protein 354A |
decreases expression |
EXP |
Erythromycin Estolate results in decreased expression of ZFP354A mRNA |
CTD |
PMID:24412560 |
|
NCBI chr10:35,396,242...35,408,065
Ensembl chr10:35,396,231...35,408,068
|
|
G |
Zfp574 |
zinc finger protein 574 |
increases expression |
EXP |
Erythromycin Estolate results in increased expression of ZFP574 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:80,667,984...80,678,257
Ensembl chr 1:80,664,259...80,679,427
|
|
|
G |
Slc51a |
solute carrier family 51 subunit alpha |
multiple interactions |
ISO |
Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid]; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid]; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid]; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid] |
CTD |
PMID:32294204 |
|
NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485
|
|
G |
Slc51b |
solute carrier family 51 subunit beta |
multiple interactions |
ISO |
Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycochenodeoxycholic Acid]; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Glycocholic Acid]; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurochenodeoxycholic Acid]; Fidaxomicin inhibits the reaction [[SLC51A protein binds to SLC51B protein] which results in increased uptake of Taurocholic Acid] |
CTD |
PMID:32294204 |
|
NCBI chr 8:65,931,891...65,934,893
Ensembl chr 8:65,931,890...65,940,145
|
|
|
G |
Acly |
ATP citrate lyase |
affects response to substance |
ISO |
ACLY protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Arf1 |
ADP-ribosylation factor 1 |
affects response to substance |
ISO |
ARF1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr10:43,997,983...44,014,543
Ensembl chr10:43,997,986...44,014,434
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
affects response to substance |
ISO |
ATP5B protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273
|
|
G |
Atp5pb |
ATP synthase peripheral stalk-membrane subunit b |
affects response to substance |
ISO |
ATP5F1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 2:193,424,138...193,435,418
Ensembl chr 2:193,424,047...193,435,418
|
|
G |
Atp5pd |
ATP synthase peripheral stalk subunit d |
affects response to substance |
ISO |
ATP5H protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr10:100,657,700...100,662,960
Ensembl chr10:100,657,708...100,663,479
|
|
G |
Atp5po |
ATP synthase peripheral stalk subunit OSCP |
affects response to substance |
ISO |
ATP5O protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr11:31,165,218...31,171,530
Ensembl chr11:31,165,217...31,171,592
|
|
G |
Atrx |
ATRX, chromatin remodeler |
affects response to substance |
ISO |
ATRX protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr X:70,850,981...70,997,330
Ensembl chr X:70,850,981...70,997,330
|
|
G |
Clpp |
caseinolytic mitochondrial matrix peptidase proteolytic subunit |
affects response to substance |
ISO |
CLPP protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 9:1,831,680...1,837,700
Ensembl chr 9:1,830,311...1,837,693
|
|
G |
Clpx |
caseinolytic mitochondrial matrix peptidase chaperone subunit X |
affects response to substance |
ISO |
CLPX protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 8:65,805,460...65,845,643
Ensembl chr 8:65,805,511...65,845,082
|
|
G |
Cs |
citrate synthase |
affects response to substance |
ISO |
CS protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Dazap1 |
DAZ associated protein 1 |
affects response to substance |
ISO |
DAZAP1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 7:9,423,673...9,448,116
Ensembl chr 7:9,424,178...9,538,818
|
|
G |
Eif2ak1 |
eukaryotic translation initiation factor 2 alpha kinase 1 |
affects response to substance |
ISO |
EIF2AK1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr12:10,710,771...10,744,597
Ensembl chr12:10,705,874...10,744,573
|
|
G |
Eif4g1 |
eukaryotic translation initiation factor 4 gamma 1 |
affects response to substance |
ISO |
EIF4G1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr11:80,221,919...80,241,958
Ensembl chr11:80,221,919...80,241,941
|
|
G |
Fbxo11 |
F-box protein 11 |
affects response to substance |
ISO |
FBXO11 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 6:6,486,761...6,562,664
Ensembl chr 6:6,486,015...6,562,662
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Josamycin results in increased expression of FOS mRNA; Josamycin results in increased expression of FOS protein |
CTD |
PMID:32454074 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
affects response to substance |
ISO |
GADD45A protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gfm2 |
GTP dependent ribosome recycling factor mitochondrial 2 |
affects response to substance |
ISO |
GFM2 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 2:28,449,452...28,488,200
Ensembl chr 2:28,449,517...28,488,197
|
|
G |
Gpi |
glucose-6-phosphate isomerase |
decreases response to substance |
ISO |
GPI protein results in decreased susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:86,828,216...86,856,086
|
|
G |
Hk2 |
hexokinase 2 |
decreases response to substance |
ISO |
HK2 protein results in decreased susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hnrnpa1 |
heterogeneous nuclear ribonucleoprotein A1 |
affects response to substance |
ISO |
HNRNPA1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 7:134,375,318...134,381,610
Ensembl chr 7:134,375,150...134,381,609
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions decreases expression |
ISO |
Ribomunyl inhibits the reaction [Josamycin results in decreased expression of ITGB2 protein] |
CTD |
PMID:8096833 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Map2k3 |
mitogen activated protein kinase kinase 3 |
affects response to substance |
ISO |
MAP2K3 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492
|
|
G |
Map3k4 |
mitogen activated protein kinase kinase kinase 4 |
decreases response to substance |
ISO |
MAP3K4 protein results in decreased susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 1:48,431,801...48,519,358
Ensembl chr 1:48,431,830...48,519,358
|
|
G |
Me2 |
malic enzyme 2 |
affects response to substance |
ISO |
ME2 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr18:67,350,833...67,400,987
Ensembl chr18:67,355,795...67,400,987
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
decreases expression |
ISO |
Josamycin results in decreased expression of COX2 protein |
CTD |
PMID:31915244 |
|
NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Mtfmt |
mitochondrial methionyl-tRNA formyltransferase |
decreases response to substance |
ISO |
MTFMT protein results in decreased susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 8:65,953,787...65,971,841
Ensembl chr 8:65,953,767...65,971,841
|
|
G |
Mtif2 |
mitochondrial translational initiation factor 2 |
decreases response to substance |
ISO |
MTIF2 protein results in decreased susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr14:103,265,808...103,285,733
Ensembl chr14:103,270,039...103,285,728
|
|
G |
Mtif3 |
mitochondrial translational initiation factor 3 |
decreases response to substance |
ISO |
MTIF3 protein results in decreased susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr12:8,126,193...8,140,706
Ensembl chr12:8,126,276...8,140,470
|
|
G |
Ndufb8 |
NADH:ubiquinone oxidoreductase subunit B8 |
affects response to substance |
ISO |
NDUFB8 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 1:243,408,659...243,413,701
Ensembl chr 1:243,408,619...243,413,817
|
|
G |
Npm1 |
nucleophosmin 1 |
affects response to substance |
ISO |
NPM1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645
|
|
G |
Pcm1 |
pericentriolar material 1 |
affects response to substance |
ISO |
PCM1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr16:51,008,315...51,105,261
Ensembl chr16:51,008,315...51,105,091
|
|
G |
Pfkp |
phosphofructokinase, platelet |
decreases response to substance |
ISO |
PFKP protein results in decreased susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr17:63,729,743...63,794,021
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Ppp1r15b |
protein phosphatase 1, regulatory subunit 15B |
affects response to substance |
ISO |
PPP1R15B protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr13:44,577,840...44,585,737
Ensembl chr13:44,577,932...44,585,737
|
|
G |
Ppp2r2a |
protein phosphatase 2, regulatory subunit B, alpha |
affects response to substance |
ISO |
PPP2R2A protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr15:41,204,659...41,263,924
Ensembl chr15:41,204,200...41,263,924
|
|
G |
Prkdc |
protein kinase, DNA-activated, catalytic subunit |
affects response to substance |
ISO |
PRKDC protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952
|
|
G |
Rtraf |
RNA transcription, translation and transport factor |
affects response to substance |
ISO |
RTRAF protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr15:4,447,243...4,457,973
Ensembl chr15:4,442,573...4,457,972
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
affects response to substance |
ISO |
SLC16A1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Smg1 |
SMG1, nonsense mediated mRNA decay associated PI3K related kinase |
affects response to substance |
ISO |
SMG1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 1:172,441,892...172,543,667
Ensembl chr 1:172,444,936...172,543,698
|
|
G |
Smg7 |
SMG7 nonsense mediated mRNA decay factor |
affects response to substance |
ISO |
SMG7 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr13:64,986,145...65,050,698
Ensembl chr13:64,987,434...65,050,582
|
|
G |
Strap |
serine/threonine kinase receptor associated protein |
affects response to substance |
ISO |
STRAP protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 4:170,646,042...170,660,291
Ensembl chr 4:170,646,001...170,660,828
|
|
G |
Taf3 |
TATA-box binding protein associated factor 3 |
affects response to substance |
ISO |
TAF3 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr17:68,455,389...68,608,367
Ensembl chr17:68,423,909...68,608,367
|
|
G |
Taf4 |
TATA-box binding protein associated factor 4 |
affects response to substance |
ISO |
TAF4 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 3:167,017,992...167,083,413
Ensembl chr 3:167,017,993...167,083,356
|
|
G |
Tpx2 |
TPX2, microtubule nucleation factor |
affects response to substance |
ISO |
TPX2 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 3:141,318,428...141,360,684
Ensembl chr 3:141,318,455...141,360,468
|
|
G |
Triap1 |
TP53 regulated inhibitor of apoptosis 1 |
affects response to substance |
ISO |
TRIAP1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr12:41,267,534...41,270,053
Ensembl chr12:41,267,549...41,270,042
|
|
G |
Ubap2l |
ubiquitin associated protein 2-like |
affects response to substance |
ISO |
UBAP2L protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr 2:175,438,703...175,494,085
Ensembl chr 2:175,438,703...175,493,998
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
affects response to substance |
ISO |
VDAC1 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
G |
Vdac2 |
voltage-dependent anion channel 2 |
affects response to substance |
ISO |
VDAC2 protein affects the susceptibility to Josamycin |
CTD |
PMID:31915244 |
|
NCBI chr15:2,462,877...2,476,802
Ensembl chr15:2,463,056...2,476,553
|
|
|
G |
Clu |
clusterin |
increases expression |
ISO |
Natamycin results in increased expression of CLU mRNA |
CTD |
PMID:22863853 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cp |
ceruloplasmin |
increases expression |
ISO |
Natamycin results in increased expression of CP mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Fga |
fibrinogen alpha chain |
increases expression |
ISO |
Natamycin results in increased expression of FGA mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 2:168,365,364...168,381,533
Ensembl chr 2:168,374,120...168,381,528
|
|
G |
Fgg |
fibrinogen gamma chain |
increases expression |
ISO |
Natamycin results in increased expression of FGG mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases expression |
ISO |
Natamycin results in increased expression of HAVCR1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Krt19 |
keratin 19 |
increases expression |
ISO |
Natamycin results in increased expression of KRT19 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
Natamycin results in increased expression of LCN2 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
ISO |
Natamycin results in increased expression of SPP1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
Natamycin results in increased expression of TIMP1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Nystatin inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:12614848 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
Nystatin inhibits the reaction [resveratrol affects the localization of CASP8 protein] |
CTD |
PMID:12902349 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cav1 |
caveolin 1 |
multiple interactions |
ISO |
Nystatin inhibits the reaction [Quercetin affects the localization of CAV1 protein] |
CTD |
PMID:17876056 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cd40 |
CD40 molecule |
increases expression |
ISO |
Nystatin results in increased expression of CD40 protein |
CTD |
PMID:16374455 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd80 |
Cd80 molecule |
increases expression |
ISO |
Nystatin results in increased expression of CD80 protein |
CTD |
PMID:16374455 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
Nystatin results in increased expression of CD86 protein |
CTD |
PMID:16374455 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Clu |
clusterin |
increases expression |
ISO |
Nystatin results in increased expression of CLU mRNA |
CTD |
PMID:22863853 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cp |
ceruloplasmin |
increases expression |
ISO |
Nystatin results in increased expression of CP mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions |
ISO |
Nystatin inhibits the reaction [resveratrol affects the localization of FADD protein] |
CTD |
PMID:12902349 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
Nystatin inhibits the reaction [resveratrol affects the localization of FAS protein] |
CTD |
PMID:12902349 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fga |
fibrinogen alpha chain |
increases expression |
ISO |
Nystatin results in increased expression of FGA mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 2:168,365,364...168,381,533
Ensembl chr 2:168,374,120...168,381,528
|
|
G |
Fgg |
fibrinogen gamma chain |
increases expression |
ISO |
Nystatin results in increased expression of FGG mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases expression |
ISO |
Nystatin results in increased expression of HAVCR1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
Nystatin results in increased expression of ICAM1 protein |
CTD |
PMID:16374455 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Nystatin results in increased expression of IL1B mRNA; Nystatin results in increased expression of IL1B protein |
CTD |
PMID:16374455 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
Nystatin results in increased expression of IL6 protein |
CTD |
PMID:16374455 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Krt18 |
keratin 18 |
increases expression |
ISO |
Nystatin results in increased expression of KRT18 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
|
|
G |
Krt19 |
keratin 19 |
increases expression |
ISO |
Nystatin results in increased expression of KRT19 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt8 |
keratin 8 |
increases expression |
ISO |
Nystatin results in increased expression of KRT8 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
Nystatin results in increased expression of LCN2 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
Nystatin inhibits the reaction [4-ethylphenol results in increased phosphorylation of MAPK1 protein]; Nystatin inhibits the reaction [4-propylphenol results in increased phosphorylation of MAPK1 protein]; Nystatin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; Nystatin inhibits the reaction [Diethylstilbestrol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Nystatin inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Nystatin inhibits the reaction [Estradiol results in increased phosphorylation of MAPK1 protein]; Nystatin inhibits the reaction [Estriol results in increased phosphorylation of MAPK1 protein]; Nystatin inhibits the reaction [Estrone results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:15072920 PMID:22230296 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
Nystatin inhibits the reaction [4-ethylphenol results in increased phosphorylation of MAPK3 protein]; Nystatin inhibits the reaction [4-propylphenol results in increased phosphorylation of MAPK3 protein]; Nystatin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Nystatin inhibits the reaction [Diethylstilbestrol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Nystatin inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Nystatin inhibits the reaction [Estradiol results in increased phosphorylation of MAPK3 protein]; Nystatin inhibits the reaction [Estriol results in increased phosphorylation of MAPK3 protein]; Nystatin inhibits the reaction [Estrone results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15072920 PMID:22230296 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Prnp |
prion protein |
multiple interactions |
ISO |
Nystatin inhibits the reaction [Copper Sulfate results in increased uptake of and affects the localization of PRNP protein] |
CTD |
PMID:11994310 |
|
NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937
|
|
G |
Rel |
REL proto-oncogene, NF-kB subunit |
increases activity |
ISO |
Nystatin results in increased activity of REL protein |
CTD |
PMID:16374455 |
|
NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases activity |
ISO |
Nystatin results in increased activity of RELA protein |
CTD |
PMID:16374455 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
ISO |
Nystatin results in increased expression of SPP1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
Nystatin results in increased expression of TIMP1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
multiple interactions |
ISO |
Nystatin inhibits the reaction [Quercetin affects the localization of TNFRSF10A protein] |
CTD |
PMID:17876056 |
|
NCBI chr15:44,839,818...44,867,582
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Vim |
vimentin |
increases expression |
ISO |
Nystatin results in increased expression of VIM mRNA |
CTD |
PMID:22863853 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Map3k7 |
mitogen activated protein kinase kinase kinase 7 |
increases activity |
EXP |
Oligomycin increases activity of Map3k7 protein in cardiac muscle cells |
RGD |
PMID:17085580 |
RGD:155791450 |
NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597
|
|
|
G |
Atp6v1h |
ATPase H+ transporting V1 subunit H |
multiple interactions |
ISO |
[PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of ATP6V1H mRNA |
CTD |
PMID:28366621 |
|
NCBI chr 5:14,379,029...14,484,703
Ensembl chr 5:14,378,257...14,537,962
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
oligomycin A inhibits the reaction [bisphenol A results in increased expression of BCL2 protein] |
CTD |
PMID:24909818 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions |
ISO |
oligomycin A inhibits the reaction [bisphenol A results in increased expression of CCNA2 protein] |
CTD |
PMID:24909818 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
oligomycin A inhibits the reaction [bisphenol A results in increased expression of CCNB1 protein] |
CTD |
PMID:24909818 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[bisphenol A co-treated with oligomycin A] results in decreased expression of CCND1 protein |
CTD |
PMID:24909818 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
[bisphenol A co-treated with oligomycin A] results in decreased expression of CCNE1 protein |
CTD |
PMID:24909818 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cd14 |
CD14 molecule |
increases expression |
ISO |
oligomycin A results in increased expression of CD14 protein |
CTD |
PMID:26036281 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Fut4 |
fucosyltransferase 4 |
increases expression |
ISO |
oligomycin A results in increased expression of FUT4 protein |
CTD |
PMID:26036281 |
|
NCBI chr 8:11,586,721...11,590,682
Ensembl chr 8:11,586,721...11,590,682
|
|
G |
Lamp1 |
lysosomal-associated membrane protein 1 |
multiple interactions |
ISO |
[PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of LAMP1 mRNA |
CTD |
PMID:28366621 |
|
NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883
|
|
G |
Pink1 |
PTEN induced kinase 1 |
multiple interactions |
ISO |
[PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of ATP6V1H mRNA; [PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of LAMP1 mRNA; [PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of TFEB mRNA; PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] affects the localization of PRKN protein]; PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] affects the localization of TFEB protein]; PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] results in increased expression of SQSTM1 mRNA]; PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]; Trifluoperazine affects the reaction [PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] affects the localization of TFEB protein]] |
CTD |
PMID:28366621 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO |
[oligomycin A co-treated with Antimycin A] affects the localization of PRKN protein; PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] affects the localization of PRKN protein] |
CTD |
PMID:28366621 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[oligomycin A co-treated with Antimycin A] results in increased expression of SQSTM1 mRNA; PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] results in increased expression of SQSTM1 mRNA] |
CTD |
PMID:28366621 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tfeb |
transcription factor EB |
multiple interactions |
ISO |
[oligomycin A co-treated with Antimycin A] affects the localization of TFEB protein; [PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of TFEB mRNA; PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] affects the localization of TFEB protein]; Trifluoperazine affects the reaction [PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] affects the localization of TFEB protein]] |
CTD |
PMID:28366621 |
|
NCBI chr 9:13,198,890...13,254,726
Ensembl chr 9:13,198,891...13,254,714
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
oligomycin B results in decreased activity of KCNH2 protein |
CTD |
PMID:24052561 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
decreases expression multiple interactions |
ISO |
monorden results in decreased expression of AHR protein benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [monorden results in decreased expression of AHR protein] |
CTD |
PMID:20057149 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
monorden inhibits the reaction [Demecolcine results in increased activity of CASP3 protein] |
CTD |
PMID:12530016 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Eln |
elastin |
increases expression |
ISO |
monorden results in increased expression of ELN protein |
CTD |
PMID:21880723 |
|
NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases expression |
ISO |
monorden analog results in decreased expression of ESR1 protein; monorden results in decreased expression of ESR1 protein |
CTD |
PMID:11448926 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
EXP |
monorden inhibits the reaction [cobaltous chloride results in increased expression of and affects the localization of GJA1 protein] |
CTD |
PMID:29155206 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
[monorden co-treated with cobaltous chloride] results in increased expression of HIF1A protein |
CTD |
PMID:29155206 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
increases expression |
ISO |
monorden analog results in increased expression of HSPA1A protein; monorden results in increased expression of HSPA1A protein |
CTD |
PMID:11448926 |
|
NCBI chr20:3,870,765...3,873,221
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
monorden inhibits the reaction [IL1B protein results in decreased expression of VLDLR protein] |
CTD |
PMID:15808840 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity decreases expression |
ISO |
monorden results in decreased activity of KCNH2 protein monorden results in decreased expression of KCNH2 protein modified form |
CTD |
PMID:12775586 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
monorden inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:15583003 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
P2rx1 |
purinergic receptor P2X 1 |
multiple interactions |
EXP |
monorden promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1] |
CTD |
PMID:11930156 |
|
NCBI chr10:57,618,586...57,633,648
Ensembl chr10:57,618,586...57,633,623
|
|
G |
Pgr |
progesterone receptor |
decreases expression |
ISO |
monorden analog results in decreased expression of PGR protein alternative form |
CTD |
PMID:11448926 |
|
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
affects phosphorylation |
ISO |
monorden affects the phosphorylation of RB1 protein |
CTD |
PMID:21880723 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rngtt |
RNA guanylyltransferase and 5'-phosphatase |
decreases expression |
ISO |
monorden results in decreased expression of RNGTT protein |
CTD |
PMID:30166341 |
|
NCBI chr 5:47,706,929...47,913,297
Ensembl chr 5:47,706,799...47,913,295
|
|
G |
Vldlr |
very low density lipoprotein receptor |
multiple interactions |
EXP |
monorden inhibits the reaction [IL1B protein results in decreased expression of VLDLR protein] |
CTD |
PMID:15808840 |
|
NCBI chr 1:224,813,539...224,850,400
Ensembl chr 1:224,814,377...224,845,920
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases activity |
ISO |
spinosad inhibits the reaction [ABCB1 protein results in increased transport of calcein AM]; spinosad inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; spinosad inhibits the reaction [ABCB1 protein results in increased transport of Ivermectin] spinosad results in decreased activity of ABCB1 protein |
CTD |
PMID:21321059 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
decreases response to substance |
ISO |
CHRNA7 protein mutant form results in decreased susceptibility to spinosad |
CTD |
PMID:23016960 |
|
NCBI chr 1:116,715,286...116,837,223
Ensembl chr 1:116,714,711...116,837,240
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
Troleandomycin inhibits the reaction [ABCB1 protein results in increased secretion of fluorexon]; Troleandomycin inhibits the reaction [ABCB1 protein results in increased secretion of Vinblastine] Troleandomycin inhibits the reaction [ABCB1A protein results in increased secretion of fluorexon] |
CTD |
PMID:12235267 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions decreases activity increases expression increases activity |
ISO |
[Troleandomycin results in decreased activity of CYP3A4 protein] which results in decreased chemical synthesis of N-desmethyltamoxifen; [Troleandomycin results in decreased activity of CYP3A4 protein] which results in decreased metabolism of Tamoxifen; Troleandomycin inhibits the reaction [CYP3A4 protein results in decreased methylation of adinazolam]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Cholecalciferol]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased metabolism of 4,5-dihydropyrazole-1,5-dicarboxylic acid 1-((4-chlorophenyl)-amide) 5-(2-oxo-2H-(1,3')bipyridinyl-6'-yl)-amide]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased metabolism of Fluoxetine]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased metabolism of laquinimod]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased metabolism of Midazolam]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased metabolism of triflumuron]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased oxidation of Methylenebis(chloroaniline)]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased oxidation of Nifedipine]; Troleandomycin promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]; Troleandomycin results in increased expression of and results in increased activity of CYP3A4 protein Troleandomycin results in increased expression of CYP3A4 mRNA Troleandomycin results in increased activity of CYP3A4 protein |
CTD |
PMID:1740010 PMID:2271712 PMID:9512926 PMID:9600717 PMID:11409940 PMID:11752104 PMID:12467917 PMID:12695342 PMID:14652237 PMID:15005856 PMID:15557344 PMID:15764719 PMID:15860655 PMID:16049126 PMID:16207822 PMID:16416302 PMID:18505790 PMID:19299527 PMID:19697924 PMID:20863320 PMID:31082524 More...
|
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression |
EXP |
Troleandomycin results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:12971794 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions decreases activity |
ISO |
Troleandomycin inhibits the reaction [CYP3A5 protein affects the metabolism of Alfentanil] Troleandomycin results in decreased activity of CYP3A5 protein |
CTD |
PMID:15557344 PMID:15731592 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Fn1 |
fibronectin 1 |
increases expression |
EXP |
Troleandomycin results in increased expression of FN1 mRNA |
CTD |
PMID:12971794 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression |
EXP |
Troleandomycin results in increased expression of GSTA2 mRNA |
CTD |
PMID:12971794 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Madcam1 |
mucosal vascular addressin cell adhesion molecule 1 |
multiple interactions |
ISO |
Troleandomycin inhibits the reaction [TNF protein results in increased expression of MADCAM1 protein] |
CTD |
PMID:12388057 |
|
NCBI chr 7:10,036,301...10,039,703
Ensembl chr 7:10,036,301...10,039,703
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
Troleandomycin binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:15039302 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Troleandomycin inhibits the reaction [TNF protein results in increased expression of MADCAM1 protein] |
CTD |
PMID:12388057 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Il2 |
interleukin 2 |
increases expression affects secretion |
ISO |
muconomycin A results in increased expression of IL2 mRNA muconomycin A affects the secretion of IL2 protein |
CTD |
PMID:8560498 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il4 |
interleukin 4 |
affects secretion increases expression |
ISO |
muconomycin A affects the secretion of IL4 protein muconomycin A results in increased expression of IL4 mRNA |
CTD |
PMID:8560498 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
affects secretion |
ISO |
muconomycin A affects the secretion of IL5 protein |
CTD |
PMID:8560498 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
muconomycin A results in increased expression of IL6 mRNA |
CTD |
PMID:8560498 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|